



Universiteit  
Leiden  
The Netherlands

## Optimizing antiseizure medication treatment in glioma patients with epilepsy

Meer, P.B. van der

### Citation

Meer, P. B. van der. (2023, November 2). *Optimizing antiseizure medication treatment in glioma patients with epilepsy*. Retrieved from <https://hdl.handle.net/1887/3655923>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3655923>

**Note:** To cite this publication please use the final published version (if applicable).



## PART I

Antiseizure medication efficacy



## CHAPTER 2

### Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review

Neuro-Oncology Practice. 2021;8(5):501-517

Pim B. van der Meer\*, Marjolein E. de Bruin\*

Linda Dirven

Martin J.B. Taphoorn

Johan A.F. Koekkoek

\*Both authors contributed equally

## Abstract

### Background

Comprehensive data on the efficacy and tolerability of AED treatment in glioma patients with epilepsy is currently lacking. In this systematic review we specifically assessed the efficacy of AEDs in patients with a grade II-IV glioma.

### Methods

Electronic databases PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane library were searched up to June 2020. Three different outcomes for both mono- and polytherapy were extracted from all eligible articles: (I) seizure freedom; (II)  $\geq 50\%$  reduction in seizure frequency; and (III) treatment failure. Weighted averages (WA) were calculated for outcomes at 6 and 12 months.

### Results

A total of 66 studies were included. Regarding the individual outcomes on the efficacy of monotherapy, the highest seizure freedom rate at 6 months was with phenytoin (WA=72%) while at 12 months pregabalin (WA=75%) and levetiracetam (WA=74%) showed highest efficacy. Concerning  $\geq 50\%$  seizure reduction rates, levetiracetam showed highest efficacy at 6 and 12 months (WAs of 82% and 97%, respectively). However, treatment failure rates at 12 months were highest for phenytoin (WA=34%) and pregabalin (41%). When comparing the described polytherapy combinations with follow-up of  $\geq 6$  months, levetiracetam combined with phenytoin was most effective followed by levetiracetam combined with valproic acid.

### Conclusion

Given the heterogeneous patient populations and the low scientific quality across the different studies, seizure rates need to be interpreted with caution. Based on the current limited evidence, with the ranking of AEDs being confined to the AEDs studied, levetiracetam, phenytoin and pregabalin seem to be most effective as AED monotherapy in glioma patients with epilepsy, with levetiracetam showing the lowest treatment failure rate, compared to the other AEDs studied.

---

### Keywords

Brain tumor, glioma, epilepsy, seizures, antiepileptic drugs

## Introduction

Gliomas are the most common malignant primary brain tumors in adults, with glioblastoma accounting for the majority. Epileptic seizures occur frequently in glioma patients, either as a presenting symptom or during the course of the disease. The epileptogenicity of the tumor is inversely related with its growth rate.<sup>1-3</sup> The incidence of seizures ranges from 60 to 85% in patients with diffuse low-grade glioma and from 30 to 50% in patients with glioblastoma.<sup>1</sup> Epilepsy results in impaired social and economic participation, an increase in morbidity and mortality, and adversely affect health-related quality of life (HRQoL) in glioma patients. Both epilepsy and the use of antiepileptic drugs (AEDs) may worsen neurocognitive functioning, which subsequently has a negative impact on HRQoL.<sup>4,5</sup> Since a reduction in seizure frequency is associated with less morbidity and improved HRQoL, achieving sustained seizure control is one of the main treatment goals in glioma patients who develop brain tumor-related epilepsy (BTRE).<sup>4,6</sup>

Both anticonvulsant and antitumor treatment including surgical resection, radiotherapy and chemotherapy may contribute to seizure control.<sup>6-10</sup> The efficacy of primary prophylactic treatment with AEDs has not been demonstrated and according to several guidelines, patients should not receive primary anticonvulsant prophylaxis.<sup>11-13</sup> However, all brain tumor patients who experience a first seizure should be treated with AEDs because of the high risk of seizure recurrence.<sup>11, 14-16</sup> Treatment with AEDs can be challenging due to multidrug-resistance, adverse effects (AEs), and potential interactions between AEDs and chemotherapeutic agents.<sup>1, 17</sup> The epileptogenic mechanisms and drug targets in glioma patients are thought to be different from the general epilepsy population as possible explanation for drug-resistance.<sup>17</sup> Indeed, refractory epilepsy (i.e. failure to achieve seizure freedom even after AED polytherapy) is reported in ~20% of glioma patients following initial treatment and higher in patients with lowgrade gliomas (30-35%).<sup>18</sup> Moreover, when compared to other epilepsy patients, AEs of AEDs occur more frequently in brain tumor patients.<sup>17</sup> When patients have become seizure free, seizure recurrence is often associated with tumor progression or recurrence.<sup>19, 20</sup>

The choice for a specific AED for glioma patients with epilepsy is determined by multiple factors, including availability, tolerability, efficacy, comorbidity, costs, ease of administration, titration schemes, pharmacokinetic characteristics, but also the physicians' preference.<sup>21</sup> General consensus exists that AEDs with less or no drug-to-drug interactions, like levetiracetam (LEV), lamotrigine (LTG), perampanel (PER), brivaracetam (BRV), zonisamide (ZNS) and lacosamide (LCM), are preferable to enzyme-inducing AEDs, such as phenobarbital (PB), phenytoin (PHT) or carbamazepine (CBZ).<sup>19, 21-23</sup> However, comprehensive data on efficacy and tolerability of anticonvulsant treatment in glioma patients is currently lacking, while it may guide physicians in the selection of AEDs.<sup>24</sup> We performed a systematic review in which we specifically assessed the efficacy of AEDs in patients with a grade II-IV glioma.

## Methods

### Search strategy

We performed a literature review in the electronic databases PubMed/MEDLINE, EMBASE, Web of Science and Cochrane library up to June 1<sup>st</sup> 2020, for screening and selecting studies we followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The search included a combination of search terms related to “glioma”, “epilepsy”, “antiepileptic drugs” and “efficacy”. The complete search strategy is described in Supplementary Table 1. Two authors (MB and PM) independently screened the articles by title and abstract, and served as reviewers of all potentially relevant full-text articles. Reference lists from the included full-text articles were searched manually for additional sources. Inclusion criteria were: (I) adult patients with BTRE, (II)  $\geq 50\%$  of patients with a histologically proven or suspected glioma, or outcomes categorized by histology, (III)  $\geq 10$  patients treated with the same AED, (IV) AED efficacy or effectiveness reported, and (V) written in English and published in a peer-reviewed journal. Exclusion criteria were: (I)  $\geq 50\%$  of patients treated with perioperative AED prophylaxis and no separate information of seizure outcome regarding this group and patients treated symptomatically, (II) no description of the different types of AEDs prescribed, and (III) no documentation of outcomes per AED in case  $< 50\%$  of patients received the same AED, (IV) articles focusing on treatment of a status epilepticus. Information was retrieved from interventional (randomized and non-randomized) and observational studies (cohort, case-control, and case-series).

### Data extraction and selection criteria

For each selected study, we extracted the following characteristics: study design, number of patients recruited and number of patients using (prophylactic) AEDs, histology, type of AEDs, duration of follow-up, and AED efficacy. As a measure of AED efficacy, defined as the ability of an AED to achieve seizure freedom or reduction, three different outcomes were extracted: (I) seizure freedom; (II)  $\geq 50\%$  reduction in seizure frequency, including seizure freedom; and (III) treatment failure, defined as discontinuation of the initiated AED or the need to add-on a second AED due to inefficacy, AEs and/or other reasons.


For this review, we focused on seizure outcomes at 6 and 12 months, based on clinical relevance and availability in studies. We separately described studies with other time points for follow-up or in case no follow-up duration was mentioned (Supplementary Table 2, 3, and 4). Weighted average (WA) was calculated for outcomes with a similar follow-up duration to control for the varying number of patients included in the studies (Supplementary Table 5). The WA is the sum of outcomes in each study multiplied by a weighting factor, which is determined by dividing the amount of patients from that study by the total number of patients from all suitable studies.




To provide a clear overview, studies were categorized according to the AED(s) prescribed and discussed in the tables in more detail under the heading of the AED prescribed most frequently. Outcomes were discussed for mono- and polytherapy separately. In case it was unclear what combination of AEDs was prescribed, results were discussed in the paragraph of the AED which was most commonly part of the AED polytherapy.

## Results

We retrieved 3582 unique records. After screening titles and abstracts, 193 full-text articles were assessed for further eligibility, after which 66 articles were considered eligible (Figure 1).



**Figure 1.** Literature selection procedure.



**Figure 2.** Weighted average (WA) calculated for outcomes at 6 and 12 months.  
\*No data available

### Levetiracetam (LEV)

We found 1 case series, 2 randomized controlled trials, 8 non-randomized clinical trials, 9 prospective and 16 retrospective observational studies reporting on LEV (Table 1).<sup>25-60</sup>

In total, 25 studies documented efficacy of LEV monotherapy.<sup>25-40, 48-50, 52, 54-58</sup> The 6-month seizure freedom rate was presented in 9/25 studies and varied between 39-96% (WA=60%),<sup>26, 27, 31, 33, 35, 38, 48, 55, 56</sup> while the 12-month seizure freedom rate was presented in 4/25 studies, ranging between 68-96% (WA=74%).<sup>32, 36, 54, 55</sup> A seizure reduction rate  $\geq 50\%$  at 6 months was presented in 2/25 studies and varied between 71-100% (WA=82%).<sup>26, 31</sup> One study reported a seizure reduction rate of  $\geq 50\%$  at 12 months of 97%.<sup>32</sup> The WAs of 6- and 12-month treatment failure rates, documented in 4 and 2 studies respectively, were 14% and 24% due to any reason, 10% and 6% due to inefficacy, and 1% and 15% due to AEs.<sup>26, 27, 31-33, 36</sup>

Table 1. Efficacy of levetiracetam at 6 and 12 months follow-up.

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Levetiracetam (LEV)</b>							
Bahr et al. (2012) <sup>33</sup>	Pros	N=30 (n=25)	GBM n=12; Grade III n=5; LGG n=5; MEN n=3; Unknown n=3 MET n=1; Other n=1;	LEV n=30		1 and 6 (after AED initiation)	1-Month seizure freedom LEV: 21/25=84% 1-Month treatment failure due to AEs (n=0), inefficacy (n=3), or unknown (n=0) LEV: 3/25=12%  6-Month seizure freedom LEV: 13/25=52% 6-Month treatment failure due to AEs (n=0), inefficacy (n=6), or unknown (n=1) LEV: 7/25=28%
<b>Chohan et al. (2019)<sup>51</sup></b>							
Discussed under perampanel							
De Groot et al. (2011) <sup>31</sup>	Pros clinical trial	N=35 (n=35)	GBM n=15; AODG n=6; AA n=4; A n=3; ODG n=3; AOA n=2 OA n=1	LEV n=35		6 (after AED initiation)	6-Month seizure freedom LEV: 21/35=59% 6-Month $\geq$ 50% Seizure reduction LEV: 26/35=74% 6-Month treatment failure due to AEs LEV: 1/35=3%
Dinapoli et al. (2009) <sup>26</sup>	Case series	N=18 (n=18)	GBM n=3; AA n=3; A n=3; OA n=3; ODG n=3; MEN n=2; Other n=1	LEV n=18		6 (after AED initiation)	6-Month seizure freedom LEV: 16/18=89% 6-Month $\geq$ 50% seizure reduction LEV: 18/18=100% 6-Month treatment failure due to AEs (n=0) or inefficacy (n=0) LEV=0/18=0%

Table 1. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Eseonu et al. (2018) <sup>48</sup>	Retro	N=81 (n=81), prophylactic n=36	Grade IV n=27; Grade II n=27; Grade III n=17; Other n=8; MET n=2	LEV n=46	LEV+PHT n=30; LEV+Other n=5	6 (after surgery)	6-Month seizure freedom monotherapy (excl. prophylactic) LEV:15/25=60% 6-Month seizure freedom (excl. prophylactic) LEV+PHT(+/-Other): 18/20=90%
Ius et al. (2020) <sup>54</sup>	Retro	N=155 (n=155)	A; n=111; ODG n=44	LEV n=96; CBZ n=22; PHT n=10	Other n=27	12 (after surgery)	12-Month seizure freedom: 110/155=71%
Lim et al. (2009) <sup>27</sup>	RCT, unblinded	N=29 (n=29)	GBM n=9; AA n=4; A n=4; ODG n=2; AOA n=2; AODG n=1; Grade I n=1	LEV n=20; PHT n=9		6 (after AED initiation/surgery)	6-Month seizure freedom LEV: 18/20=90% 6-Month treatment failure due to AEs (n=0), inefficacy (n=0), or unknown (n=5) LEV: 6/20=30%
Maialetti et al. (2020) <sup>56</sup>	Pros	N=33 (n=33)	HGG n=14; LGG n=12; Other n=7	LEV n=10; Other n=11	LEV+Other n=9; Other n=3	6 (after rehabilitation)	6-Month seizure freedom AEDs: 26/33=79% 6-Month ≥50% Seizure reduction AEDs: 28/33=85%
Maschio et al. (2011) <sup>32</sup>	Pros clinical trial	N=29 (n=29)	GBM n=9; AODG n=6; LGA n=5; AA n=4; MEN n=2; Other n=2; ODG n=1;	LEV n=29		12 (after AED initiation)	12-Month seizure freedom LEV: 21/29=72% 12-Month ≥50% Seizure reduction LEV: 28/29=97% 12-Month treatment failure due to AEs (n=1), inefficacy (n=2), or other (n=2) LEV: 5/29=17%
Maschio et al. (2017) <sup>43</sup>	Discussed under lacosamide						

Table 1. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Michelucci et al. (2013) <sup>35</sup>	Pros	N=100 (n=97)	GBM n=52; AA n=15; ODG n=10; A n=9; AODG n=5; Other n=4; AOA n=3; Grade I n=2;	Mono- (n=64) and polytherapy (n=33): LEV n=63; OXC n=33; PHT n=16; CBZ n=10; Other n=8		6 (after surgery)	6-Month seizure freedom AEDs: 39/100=39%
Rahman et al. (2015) <sup>38</sup>	Pros	N=81 (n=55)	GBM n=27; ODG n=20; MEN n=13; A n=8; Grade I n=7; OA n=4; Other n=2	LEV n=21; Other n=11	LEV+Other n=9; Other n=14	6 (after AED initiation)	6-Month seizure freedom AEDs: 32/55=58%
Rossetti et al. (2014) <sup>36</sup>	Discussed under pregabalin						
Rudà et al. (2018) <sup>44</sup>	Discussed under lacosamide						
Rudà et al. (2020) <sup>60</sup>	Discussed under lacosamide						
Solomons et al. (2019) <sup>39</sup>	Retro	N=74 (n=66)	ODG n=32; A n=26; OA n=7; Other n=9		Mono- and polytherapy: LEV +/- Other n=44; Other n=22	12 (after AED initiation)	12-Month seizure freedom 38/66=57%

See supplementary table for the following articles. LEV=Bech et al. (2018), Bernitsson et al. (2018), Calatuzzolo et al. (2009), Cardona et al. (2018), Casas Perera et al. (2019), Feyissa et al. (2019), Haggiagi & Avila (2018), Kerkhof et al. (2013), Kerkhof et al. (2019), Maschio et al. (2006), Merrel et al. (2010), Newton et al. (2006), Romoli et al. (2019), Rosati et al. (2010), Saria et al. (2013), Suzuki et al. (2010), Usery et al. (2010), Wagner et al. (2003), Wychowski et al. (2013)

**Antiepileptic drugs (AEDS):** CBZ=Carbamazepine; LEV=Levetiracetam; OXC=Oxcarbazepine; PHT=Phenytoin, **Histology:** A=(Pleomorphic) astrocytoma grade II; AA=Anaplastic (pleomorphic) astrocytoma; AOA=Anaplastic oligoastrocytoma; AODG=Anaplastic oligodendroglioma; GBM=Glioblastoma; HGG=High grade glioma; LGG=Low grade glioma; MEN=Meningioma; MET=Metastasis; OA=Oligoastrocytoma; ODG=Oligodendroglioma grade II, **General abbreviations:** AEs=Adverse effects; Excl.=excluding; N=number of patients; Pros=prospective; RCT=randomized controlled trial; Retro=retrospective

In total, 13 studies documented efficacy of polytherapy including LEV.<sup>25, 41-48, 51, 53, 59, 60</sup> The 6-month seizure freedom rate was presented in 5/13 studies and ranged between 28-90% (WA 43%),<sup>43, 44, 48, 51, 60</sup> while the 12-month seizure freedom rate was presented in 2/13 studies, ranging between 44-58% (WA 55%).<sup>51, 59</sup> A  $\geq 50\%$  seizure reduction rate at 6 months was presented in 4 studies and ranged between 74-77% (WA=76%).<sup>42-44, 60</sup> A total of 5 studies reported treatment failure rates of LEV polytherapy.<sup>42, 46, 47, 51, 60</sup> The 6-month treatment failure rate, documented in 2 studies, was 13% due to any reason, 2% due to inefficacy, and 5% due to AEs.<sup>51, 60</sup> One study reported a 0% treatment failure rate due to inefficacy at 12 months.<sup>51</sup>

### **Phenytoin (PHT)**

We found 1 prospective and 11 retrospective observational studies reporting on PHT (Table 2).<sup>4, 8, 28, 37, 48, 61-67</sup>

In total, 9 studies documented efficacy of PHT monotherapy.<sup>4, 8, 28, 37, 61-65</sup> The 6-month seizure freedom rate was presented in 2/9 studies and varied between 67-87% (WA=72%).<sup>8, 61</sup> while the 12-month seizure freedom rate was presented in 5/9 studies and varied between 35-77% (WA=65%).<sup>4, 8, 61, 62, 65</sup> One study reported a 34% treatment failure rate due to AEs at 12 months of PHT treatment.<sup>65</sup>

In total, 3 studies documented efficacy of polytherapy including PHT.<sup>48, 66, 67</sup> The 6-month seizure freedom rate was 90% as reported in 1/3 studies.<sup>48</sup>

### **Valproic acid (VPA)**

We found 1 prospective and 9 retrospective observational studies reporting on VPA (Table 2).<sup>4, 25, 41, 65-71</sup>

In total, 8 studies documented efficacy of VPA monotherapy.<sup>4, 25, 41, 65, 68-70</sup> Six-month seizure freedom rate was 65% as reported in one study,<sup>69</sup> while 12-month seizure freedom rate was presented in 4/8 studies and ranged between 30-62% (WA=37%).<sup>4, 65, 69, 70</sup> One study reported a 14% treatment failure rate due to inefficacy at 6 months and another study reported a 21% treatment failure rate due to AEs of VPA treatment at 12 months.<sup>65, 71</sup>

In total, 4 studies documented efficacy of polytherapy including VPA.<sup>4, 25, 41, 66, 67</sup> In these studies, no results were reported for 6 or 12 month follow-up duration.

### **Carbamazepine (CBZ)**

We found 1 prospective and 6 retrospective observational studies reporting on CBZ (Table 2).<sup>4, 8, 65-67, 72, 73</sup>

Seizure freedom rate was described in all 5 studies on CBZ monotherapy. However, one study reported on the 6-month seizure freedom rate, i.e. 28%.<sup>73</sup> The 12-month seizure freedom rate was presented in 2/5 studies and varied between 30-55% (WA=43%).<sup>4, 65</sup> One study reported a 12-month treatment failure rate of 26% due to AEs.<sup>65</sup>

In total, 2 studies documented efficacy of polytherapy including CBZ. In these studies, no results were reported for 6 or 12 month follow-up duration.

**Table 2.** Efficacy of phenytoin, valproic acid, and carbamazepine at 6 and 12 months follow-up.

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Phenytoin (PHT)</b>							
ChaiChana et al. (2009) <sup>61</sup>	Retro	N=648 (n=153)	GBM n=505; AA n=143	Preoperative AEDs: mono- (n=111) and polytherapy (n=42); PHT n=102; LEV n=13; DVX n=12; Other n=19; Unknown unclear	Unknown n=55	6 and 12 (after surgery)	6-Month seizure freedom AEDs: 79/91=87%  12-Month seizure freedom AEDs: 51/66=77%
Chang et al. (2008) <sup>8</sup>	Retro	N=332 (n=284)	A n=129; OA n=109; ODG n=95	PHT n=159; CBZ n=59; DVX n=29; PB n=26; Other n=15;	Unknown n=55	3 (before surgery), 6 and 12 (after surgery)	3-Month seizure freedom PHT: 84/159=53%; CBZ: 22/59=37%; PB: 11/26=42%; Divalproex sodium: 14/29=48%  6-Month seizure freedom AEDs: 169/253=67%  12-Month seizure freedom AEDs: 147/220=67%
<b>Discussed under levetiracetam</b>							
Eseonu et al. (2018) <sup>48</sup>							
Hwang et al. (2004) <sup>62</sup>	Retro	N=101 (n=101), prophylactic n=87	GBM n=57; AA n=27; A n=17	PHT n=101		1, 3 and 12 (after surgery)	1-Month seizure freedom (excl. prophylactic) PHT: 12/14=86%  3-Month seizure freedom (excl. prophylactic) PHT: 11/14=79%  12-Month seizure freedom (excl. prophylactic) PHT: 9/14=64%

Table 2. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Klein et al. (2003) <sup>64</sup>	Discussed under carbamazepine						
Wick et al. (2005) <sup>65</sup>	Retro	N=107 (n=107), prophylactic n=32, unclear n=7	GBM n=45; AA n=17; ODG n=16; AODG n=14; A n=13; Grade I n=1; Other n=1	PHT n=35; VPA n=34; CBZ n=27; Unclear n=11		12 (after surgery)	12-Month seizure freedom (incl. prophylactic) PHT: 17/35=49%; VPA: 19/34=56%; CBZ: 8/27=30% 12-Month treatment failure due to AEs (incl. prophylactic) PHT: 12/35=34%; VPA: 7/34=21%; CBZ: 7/27=26%;
<b>Valproic acid (VPA)</b>							
Klein et al. (2003) <sup>64</sup>	Discussed under carbamazepine						
Wang et al. (2019) <sup>71</sup>	Retro	N=41 (n=41)	Grade II n=19; Grade III n=12; Grade IV n=10	VPA n=21; LEV n=11; Other n=4	VPA+LEV n=5	6 (after surgery)	6-Month treatment failure due to inefficacy AEDs: 5/37=14%
Wick et al. (2005) <sup>65</sup>	Discussed under phenytoin						
You et al. (2012) <sup>69</sup>	Retro	N=508 (n=502), prophylactic n=154	OA n=231; A n=229; ODG n=48	VPA n=444; Other n=8; Unknown n=2	Other n=50	6 and 12 (after surgery)	6-Month seizure freedom (excl. prophylactic) AEDs: 215/329=65%. 12-Month seizure freedom (excl. Prophylactic AEDs: 90/304=30%.
Yuan et al. (2013) <sup>70</sup>	Retro	N=93 (n=65)	ODG n=36; OA n=29; A n=28	VPA n>95%; Other n<5%		12 (after surgery)	12-Month seizure freedom AEDs: 37/65=57%



Table 2. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Carbamazepine (CBZ)</b>							
Chang et al. (2008) <sup>8</sup>	Discussed under phenytoin						
Klein et al. (2003) <sup>4</sup>	Cross-sectional (seizure history retro)	N=156 (n=114)	A n=109; ODG n=38; OA n=9	CBZ n=29; VPA; n=13; PHT n=20; Other n=2	Other n=50	12 (after primary treatment)	12-Month seizure freedom CBZ: 16/29=55%; PHT 7/20=35%; VPA 8/13=62%
Warnke et al. (1997) <sup>3</sup>	Retro	N=80 (n=80), prophylactic n=8	A n=80	CBZ n=58; PHT n=12; PB n=10		6 (after radiosurgery)	6-Month seizure freedom (incl. prophylactic) CBZ: 16/58=28%
Wick et al. (2005) <sup>65</sup>	Discussed under phenytoin						

See supplementary table for the following articles. PHT: Merrel et al. (2010), Moots et al. (1995), Rosati et al. (2009), Wychowski et al. (2013), Zaatreh et al. (2002), Zaatreh et al. (2003); VPA: Breemen et al. (2009), Kerkhof et al. (2013), Simó et al. (2012), Zaatreh et al. (2002), Zaatreh et al. (2003); CBZ: Pace et al. (1998), Zaatreh et al. (2002), Zaatreh et al. (2003)

**Antiepileptic drugs (AEDs):** CBZ=Carbamazepine; DVX=Divalproex sodium; EIAEDs=Enzyme-inducing antiepileptic drugs; GBP=Gabapentin; LTG=Lamotrigine; LEV=Levetiracetam; PB=Phenobarbital; PRI=Primidone; PHT=Phenytoin; VPA=Valproic acid; **Histology:** A=(Pleomorphic) astrocytoma grade II; AA=Anaplastic (pleomorphic) astrocytoma; AOA=Anaplastic oligoastrocytoma; AODG=Anaplastic oligodendrogloma; GBM=Glioblastoma; HGG=High grade glioma; LGG=Low grade glioma; MEN=Meningioma; MET=Metastasis; OA=Oligoastrocytoma; ODG=Oligodendrogloma grade II, **General abbreviations:** AEs=Adverse effects; Excl.=excluding. Incl.=including; Pros=prospective; Retro=retrospective

**Lacosamide (LCM)**

No studies documented efficacy of LCM monotherapy. The efficacy of polytherapy including LCM was reported in 3 non-randomized clinical trials, 1 prospective and 3 retrospective observational studies (Table 3).<sup>43-45, 60, 74-76</sup> The 6-month seizure freedom rate with polytherapy including LCM was presented in 4/7 studies and varied between 26-43% (WA=33%).<sup>43, 44, 60, 74</sup> A seizure reduction rate  $\geq 50\%$  at 6 months was reported in 4 studies and varied between 66-77% (WA=73%).<sup>43, 44, 60, 74</sup> The WAs of 6-month treatment failure rates, documented in 4 studies, were 12% due to any reason, 2% due to inefficacy, and 5% due to AEs.<sup>43, 60, 75, 76</sup>

**Perampanel (PER)**

No studies documented efficacy of PER monotherapy. The efficacy of polytherapy including PER was reported in 1 non-randomized clinical trial, 1 prospective and 3 retrospective observational studies (Table 3).<sup>51, 77-80</sup>

The 6-month seizure freedom rate of polytherapy with PER was presented in 3/5 studies and ranged between 31-60% (WA=41%),<sup>51, 77, 80</sup> while the 12-month seizure freedom rate in 2/5 studies varied between 44-45% (WA=45%).<sup>51, 79</sup> Seizure reduction rates  $\geq 50\%$  at 6 and 12 months were 92% and 82%, respectively, as reported in 3 different studies.<sup>77, 79, 80</sup> Treatment failure rates with polytherapy including PER ranged between 0-17%. The WAs of 6-month treatment failure rates, documented in 3 studies, were 5% due to any reason, 0% due to inefficacy, and 5% due to AEs.<sup>51, 77, 80</sup> The WAs of 12-month treatment failure rates, documented in 2 studies, were 0% due to any reason, inefficacy and AEs.<sup>51, 79</sup>

**Pregabalin (PGB)**

We found 1 RCT reporting on PGB monotherapy and 1 non-randomized clinical trial reporting on PGB polytherapy (Table 3).<sup>36, 81</sup>

Seizure freedom rate at 12 months with PGB monotherapy was 75%, as reported in one RCT (n=52). Treatment failure rates at 12 months were 41% due to any reason, 15% due to inefficacy and 26% due to AEs.<sup>36</sup>

At 6 months, seizure freedom rate was reported in 36% and a  $\geq 50\%$  seizure reduction rate in 76% of patients on polytherapy including PGB, as reported in one non-randomized clinical trial (n= 25). Treatment failure rates with PGB polytherapy at 6 months was 28% due to any reason, 20% due to inefficacy and 8% due to AEs.<sup>81</sup>

**Oxcarbazepine (OXC)**

We found 1 non-randomized clinical trial and 1 retrospective observational study reporting on OXC monotherapy (Table 3).<sup>82, 83</sup>

As reported in 1 non-randomized clinical trial (n=25), the 12-month seizure freedom rate was 40% and a  $\geq 50\%$  seizure reduction was observed in 88% of patients.<sup>82</sup> Treatment

failure with OXC monotherapy ranged between 9-36%. The study provided reasons for the 12-month treatment failure rate: 12% due to inefficacy and 24% due to AEs.<sup>82</sup>

### **Topiramate (TPM)**

We found 1 non-randomized clinical trial and 1 retrospective observational study reporting on TPM (Table 3).<sup>84, 85</sup>

Seizure freedom rate at 6 months with TPM monotherapy was 59%, as reported in one non-randomized clinical trial (n=47).<sup>84</sup> The 12-month seizure freedom rates were reported in both studies and varied between 57-71% (WA=60%). A  $\geq 50\%$  reduction in seizure frequency at 12 months was described in both studies and ranged between 75-86% (WA=78%).<sup>84, 85</sup> One study described the treatment failure rate at 6 and 12-months of 6% and was in all cases due to AEs.<sup>84</sup>

The efficacy of polytherapy including TPM was reported in one retrospective study, 40 patients used TPM in combination with another AED. The 12-month seizure freedom rate was 60% with a  $\geq 50\%$  seizure reduction of 70%.<sup>85</sup>

### **Other AEDs**

The efficacy of polytherapy including tiagabine (TGB) was reported in 1 small prospective observational study (n=11 [Table 3]). The 12-month seizure freedom rate was 27%, and  $\geq 50\%$  seizure reduction was reported in 64% patients. Total treatment failure rate with TGB polytherapy at 12 months was 27%; 9% due to inefficacy and 18% due to AEs.<sup>86</sup>

The efficacy of polytherapy including zonisamide (ZNS) was reported in 1 small prospective observational study (n=13 [Table 3]). The 6-month seizure reduction rate  $\geq 50\%$  was 54%. No patients experienced treatment failure with ZNS polytherapy in the first 6 months.<sup>87</sup>

The efficacy of the other AEDs (PB, gabapentin (GBP), LTG, clonazepam, divalproex sodium, primidone and vigabatrin), with no outcomes reported at 6- or 12-month follow-up, was only discussed in 1 or 2 studies except for PB, which was discussed in 5 studies.

Table 3. Efficacy of lacosamide, perampanel, pregabalin, oxcarbazepine, topiramate, tiagabine, zonisamide at 6 and 12 months follow-up.

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Lacosamide (LCM)</b>						
Maschio et al. (2011) <sup>76</sup>	Pros clinical trial	N=14 (n=14)	GBM n=5; AA n=2; AOA n=2; A n=2; AODG n=1; ODG n=1; GC n=1	LCM+Other n=14	3, 6 and 9 (after AED initiation)	3-Month treatment failure due to AEs (n=1) or inefficacy (n=0) LCM: 1/14=7%  6-Month treatment failure due to AEs (n=1) or inefficacy (n=0) LCM: 1/14=7%  9-Month seizure freedom LCM: 6/14=38% 9-Month $\geq$ 50% seizure reduction LCM: 11/14=79% 9-Month treatment failure due to AEs (n=1) or inefficacy (n=0) LCM: 1/14=7%
Maschio et al. (2017) <sup>43</sup>	Pros (compared to a historical control group) clinical trial	N=25 (n=25)	A n=8; AA n=6; GBM n=5; ODG n=3; AODG n=2; AOA n=1	LCM+LEV (+/- other) n=15; LCM+Other n=10	3 and 6 (after AED initiation)	3-Month seizure freedom LCM: 8/25=32% 3-Month $\geq$ 50% seizure reduction LCM: 19/25=76% 3-Month treatment failure due to AEs (n=0), poor compliance (n=4) or inefficacy (n=1) LCM: 5/25=20%  6-Month seizure freedom LCM: 7/25=28% 6-Month $\geq$ 50% seizure reduction LCM: 19/25=76% 6-Month treatment failure due to AEs (n=0), poor compliance (n=4) or inefficacy (n=1) LCM: 5/25=20%

Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Rudà et al. (2018) <sup>44</sup>	Pros clinical trial	N=71 (n=71)	A n=44; ODG/ OA n=27	LCM+LEV(+/- Other) n=60; LCM+Other 11		3, 6 and 9 (after AED initiation)	3-Month seizure freedom LCM: 30/71=42% 3-Month ≥50% seizure reduction LCM: 53/71=75%  6-Month seizure freedom LCM: 28/65=43% 6-Month ≥50% seizure reduction LCM: 50/65=77%  9-Month seizure freedom LCM: 29/58=50% 9-Month ≥50% seizure reduction LCM: 50/58=86% 9-Month treatment failure due to AEs (n=2), inefficacy (n=1), or other reasons (n=1) LCM: 4/71=6%
Rudà et al. (2020) <sup>60</sup>	Pros	N=93 (n=93)	ODG n=32; A n=29; OA n=13; Other n=16; MEN n=3	LCM+LEV(+/- Other) n=60; LCM+Other n=33		6 (after AED initiation)	6-Month seizure freedom LCM: 30/86=35% 6-Month ≥50% seizure reduction LCM: 66/86=77% 6-Month treatment failure due to AEs (n=5), inefficacy (n=2), or other reasons (n=7) LCM: 14/93=15%
Villanueva et al. (2016) <sup>74</sup>	Retro	N=105 (n=105)	A n=42; GBM n=13; MET n=12; MEN n=11; Grade I n=10; ODG n=7; OA n=5; Other n=2; Unknown n=2; GC n=1;	LCM n=3	LCM+Other n=102	3 and 6 (after AED initiation)	3-Month seizure freedom LCM: 32/105=30% 3-Month ≥50% seizure reduction LCM: 71/105=68% 3-Month treatment failure due to AEs (n=1), inefficacy (n=0), or other reasons (n=0) LCM: 1/105=1%

Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
						6-Month seizure freedom LCM: 25/97=26% 6-Month ≥50% seizure reduction LCM: 64/97=66% 6-Month treatment failure due to AEs (n=5), inefficacy (n=1), or other reasons (n=2) LCM: 8/105=8%
<b>Perampanel (PER)</b>						
Chohan et al. (2019) <sup>51</sup>	Retro	N=18 (n=18)	GBM n=7; AA n=5; ODG n=3; A n=2; AODG; n=1	PER+LEV n=18	1, 3, 6, 9, 12 (after AED initiation)	1-Month seizure freedom: 10/18=56% 1-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  3-Month seizure freedom: 8/18=44% 3-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  6-Month seizure freedom: 8/18=44% 6-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  9-Month seizure freedom: 8/18=44% 9-Month treatment failure due to AEs or inefficacy PER: 0/18=0%
Izumoto et al. (2018) <sup>77</sup>	Retro	N=12 (n=12)	AODG n=5; AA n=3; GBM n=2; A n=1; OA n=1	PER+Other n=12	6 (after AED initiation)	12-Month seizure freedom: 8/18=44% 12-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  6-Month seizure freedom PER: 6/10=60% 6-Month ≥50% seizure reduction PER: 10/10=100% 6-Month treatment failure due to AEs PER: 1/12=8%

Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Maschio et al. (2018) <sup>79</sup>	Retro	N=11 (n=11)	A n=4; GBM n=3; AA n=2; AOA n=2	PER+Other n=11	12 (after AED initiation)	12-Month seizure freedom PER: 5/11=45% 12-Month $\geq$ 50% seizure reduction PER: 9/11=82% 12-Month treatment failure due to AEs PER: 0/11=0%
Maschio et al. (2020) <sup>80</sup>	Pros clinical trial	N=26 (n=26)	GBM n=7; AA n=7; A n=5; ODG n=3; MET n=2; MEN n=1; AOA n=1	PER+Other n=26	6 (after AED initiation)	6-Month seizure freedom PER: 8/26=31% 6-Month $\geq$ 50% seizure reduction PER: 23/26=88% 6-Month treatment failure due to AEs (n=2) or inefficacy (n=0) PER: 2/26=8%
<b>Pregabalin (PGB)</b>						
Maschio et al. (2012) <sup>81</sup>	Pros clinical trial	N=25 (n=25)	GBM n=6; AA n=4; AODG n=3; AOA n=3; A n=2; MET n=2; MEN n=2; GC n=2; OA n=1; MEN n=2	PGB+Other n=25	6 (after AED initiation)	6-Month seizure freedom PGB: 9/25=36% 6-Month $\geq$ 50% Seizure reduction PGB: 19/25=76% 6-Month treatment failure due to AEs (n=2) or inefficacy (n=5) PGB: 7/25=28%
Rossetti et al. (2014) <sup>86</sup>	RCT, unblinded phase II trial	N=52 (n=52)	HGG n=37; Recurrent tumor n=16	PGB n=27; LEV n=25	12 (after AED initiation)	12-Month seizure freedom PGB: 18/24=75%; LEV: 17/25=68% 12-Month treatment failure AEs (n=7) or inefficacy (n=4) PGB: 11/27=41%; AEs (n=7) or inefficacy (n=1) LEV: 8/25=32%
<b>Oxcarbazepine (OXC)</b>						
Maschio et al. (2012) <sup>82</sup>	Pros clinical trial	N=25 (n=25)	GBM n=12; AA n=4; GC n=3; A n=2; AODG n=1; AOA n=1; Grade I n=1; MEN n=1	OXC n=25	12 (after surgery)	12-Month seizure freedom OXC: 10/25=40% 12-Month $\geq$ 50% seizure reduction OXC: 22/25=88% 12-Month treatment failure due to AEs (n=6) or inefficacy (n=3) OXC: 9/25=36%

Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Topiramate (TPM)</b>						
Lu et al. (2009) <sup>85</sup>	Retro	N=227 (n=227)	LGG n=54; Other n=173	TPM n=14 TPM+Other n=40	12 (after AED initiation)	12-Month seizure freedom mono-, polytherapy TPM: 10/14=71%; 24/40=60% 12-Month ≥50% seizure reduction mono- and polytherapy TPM: 12/14=86%; 28/40=70%
Maschio et al. (2008) <sup>84</sup>	Pros clinical trial	N=47 (n=47)	Grade III n=20; LGG n=13; GBM n=8; MEN n=4; MET n=2	TPM n=47	3, 6 and 12 (after AED initiation)	3-Month seizure freedom TPM: 27/45=60% 3-Month ≥50% seizure reduction TPM: 34/45=76% 3-Month treatment failure due to AEs (n=2) or inefficacy (n=0) TPM: 2/47=4% 6-Month seizure freedom TPM: 26/44=59% 6-Month ≥50% seizure reduction TPM: 34/44=77% 6-Month treatment failure due to AEs (n=3) or inefficacy (n=0) TPM: 3/47=6%
<b>Tiagabine (TGB)</b>						
Striano et al. (2002) <sup>86</sup>	Pros	N=11 (n=11)	ODG n=6; A n=4; GBM n=1; A n=3; Grade I n=1	TGB+Other n=11	12 (after AED initiation)	12-Month seizure freedom TGB: 3/11=27% 12-Month ≥50% seizure reduction TGB: 7/11=64% 12-Month treatment failure due to AEs (n=2) or inefficacy (n=1) TGB: 3/11=27%



Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Zonisamide (ZNS)</b>						
Maschio et al. (2017) <sup>87</sup>	Pros	N=13 (n=13)	GBM n=6; MEN n=3; OA n=2; ODG n=1; MET n=1	ZNS+Other n=13	6 (after AED initiation)	6-Month $\geq$ 50% seizure reduction ZNS: 7/13=54% 6-Month treatment failure due to AEs (n=0) or inefficacy (n=0) ZNS= 0/13=0%

See supplementary for the following articles. LCM= Saria et al. (2013), Toledo et al. (2018); PB= Chang et al. (2008), Maschio et al. (2009), Pace et al. (1998), Zaatreh et al. (2002), Zaatreh et al. (2003); PER= Vecht et al. (2017); OXC= Maschio et al. (2009); CZP= Koekkoek et al. (2016); GBP= Zaatreh et al. (2002), Zaatreh et al. (2003); LTG= Zaatreh et al. (2002), Zaatreh et al. (2003); DVX= Chang et al. (2008), PRI= Zaatreh et al. (2003) VGB= Pace et al. (1998)

**Antiepileptic drugs (AEDs):** CBZ=Carbamazepine; CZP=Clonazepam; DVX=Divalproex sodium; GBP=Gabapentin; LCM=Lacosamide; LEV=Levetiracetam; OXC=Oxcarbazepine; PB=Phenobarbital; PGB=Prigabalin; PRI=Primidone; PHT=Phenytoin; TGB=Tiagabine; TPM=Topiramate; VGB=Vigabatrin; ZNS=Zonisamide; **Histology:** A=(Pleomorphic) astrocytoma grade II; AA=Anaplastic (pleomorphic) astrocytoma; AOA=Anaplastic oligoastrocytoma; AODG=Anaplastic oligodendroglioma; GBM=Glioblastoma; GC=Gliomatosis cerebri; HGG=High grade glioma; LGG=Low grade glioma; MEN=Meningioma; MET=Metastasis; OA=Oligoastrocytoma; ODG=Oligodendroglioma grade II, **General abbreviations:** AEs=Adverse effects; Pros=prospective; Retro=retrospective

## Discussion

In this review we summarized the current available literature on AED efficacy in patients with BTRE due to diffuse glioma. Overall, the interpretation of seizure outcome is hampered by the heterogeneous patient populations in terms of, for example, tumor histology, tumor location, seizure type, and use of concomitant medication. In addition, the effect of tumor status and concomitant antitumor treatment on the reduction in the number of seizures cannot be ruled out. Methodological limitations such as study design and inadequate statistical analysis make the results less interpretable as well. For example, methodological issues weren't always taken into account in the different studies, such as the presence of death as a competing risk.<sup>88</sup> Therefore, reported seizure rates need to be interpreted with caution. Moreover, efficacy of AEDs was not always the primary outcome in the studies, resulting in limited information available on the efficacy of specific (combinations of) AEDs, or different aspects of efficacy or time points were assessed, hampering comparability of studies.

To overcome variation with respect to the different sample sizes and reporting only a range, we calculated a WA to provide a more reliable estimate of AED efficacy. Furthermore, we purposefully chose to focus on the results for 6- and 12-month follow-up, as these time points were considered clinically relevant, most often described in the selected studies, and therefore making a comparison between AEDs possible. To better guide clinicians in their choice of AED treatment, we combined information on seizure freedom and seizure reduction with information about treatment failure.

Bearing in mind the limitations with regard to study heterogeneity, there was not one AED that clearly stood out in terms of efficacy. Indeed, based on the calculated WA's, 6-month seizure freedom rate with AED monotherapy was highest for PHT, whereas the 12-month seizure freedom rate was highest for PGB. However, the 12-months seizure freedom rate of PGB is based on only a small phase 2 study (n=52) in patients with mainly grade 3 and 4 glioma (treatment failure rate of 41%).<sup>36</sup> For achieving a  $\geq 50\%$  seizure reduction, LEV was found to be the most effective AED at 6 and 12 months. Nevertheless, a  $\geq 50\%$  seizure reduction with AED monotherapy was only mentioned for LEV/TPM and OXC. In line with the weighted data, one of the RCTs comparing LEV with PGB showed similar seizure freedom rates.<sup>36</sup> Thus, based on the currently available evidence, PHT, PGB, and LEV seem most effective as monotherapy in the treatment of epilepsy in glioma patients. It should be noted that the high seizure freedom rate of PHT at 6 months is based on only 2 retrospective studies<sup>8, 61</sup>, compared to 9 studies on LEV including one RCT at 6 months.<sup>27</sup>

The results with respect to AED polytherapy were also ambiguous. Seizure freedom rates with polytherapy at 6 months and 12 months were highest for combinations with PHT and TPM, respectively. For achieving a  $\geq 50\%$  seizure reduction, PER was found to be the

most effective AED at both 6 and 12 months, based on studies with a small number of patients including mainly malignant brain tumours. Of note, in most studies it was unclear what combination of AEDs patients were taking when they were on AED polytherapy. The four known studied combinations with outcomes  $\geq 6$  months, were LEV+PHT,<sup>89</sup> LEV+LCM,<sup>43, 44, 60</sup> PER+LEV,<sup>51</sup> and LEV+VPA.<sup>18, 41</sup> Eseonu et al. (2018) reported a 6-month seizure freedom rate of 90% (18/20 patients) when combining LEV with PHT, although this rate was reported 6 months after tumor surgery, which is known to have an antiseizure effect in glioma patients.<sup>89</sup> Considering the known combinations, LEV+VPA was second-best and showed seizure freedom rates of 54% and 59% after a minimum follow-up of 6 months.<sup>18, 41</sup>

Nonetheless, it should be emphasized that PHT and PGB were associated with relatively high percentages of treatment failure. Specifically for monotherapy, treatment failure due to AEs for PHT was 34% (WA) at 12 months, followed by PGB and CBZ with 26% (WA), treatment failure due to any reason at 6 months was highest for PGB. Less information was available on the treatment failure rates of AED polytherapy, but again PGB showed the highest rate with 28% treatment failure due to any reason, while LEV, PER and ZNS showed most favorable tolerability. These findings provide substantiation of the general consensus that has emerged over the past two decades regarding the avoidance of cytochrome P450 enzyme-inducing AEDs, such as PHT, CBZ, and PB in glioma patients, due to its potential drug-to-drug interactions.<sup>21, 22, 90</sup> In the general epilepsy population, PHT has been known for its worse tolerability compared to newer agents, such as LEV.<sup>91</sup> In glioma patients, the P450 enzyme-inducing properties of PHT and its inherent interaction with other medications and antineoplastic drugs, such as corticosteroids, lomustine, and vincristine, are considered a risk factor for the occurrence of AEs.<sup>11</sup> Among other AEDs, LEV, PGB, and LTG are predominantly excreted by the renal system and do not have P450-inducing or inhibiting properties, leading to less drug-drug interactions.<sup>92</sup> Nonetheless, of these newer non-enzyme-inducing AEDs, we found LEV to show a better tolerability than PGB, which seems likely be attributed to a higher rate of side effects in patients on PGB compared to LEV.

LEV may nowadays be the most commonly prescribed AED in patients with BTRE, probably because of its good tolerability and the possibility to titrate rapidly.<sup>93</sup> However, it is associated with psychiatric AEs and it is therefore strongly advised not to be prescribed in patients with psychiatric comorbidities.<sup>93</sup> For those patients BRV may be a promising alternative with a comparable pharmacokinetic profile but higher tolerability regarding psychiatric AEs. Otherwise, PGB is prescribed less frequently for the treatment of epilepsy,<sup>94</sup> but effective in treating neuropathic pain and anxiety disorders which are both common symptoms in glioma patients ( $\sim 20$  and  $\sim 30\%$ , respectively).<sup>95, 96</sup>

VPA has long been one of the first choice treatments in glioma patients with epilepsy partly due to its presumed antitumor effect, although a survival benefit in glioblastoma

could not be determined in a pooled analysis of prospective trials.<sup>97</sup> Due to its relatively lower seizure control rates compared to other AEDs, our data do not support VPA as first choice monotherapy. Supported by two studies, which showed reasonable seizure freedom rates, VPA can be a good option as second-line AED treatment combined with LEV in patients with uncontrolled seizures.<sup>18, 41</sup> Adverse effects of VPA include weight gain, encephalopathy, thrombocytopenia and platelet dysfunction. In addition VPA is a CYP450-inhibitor leading to drug-drug interactions and an increased toxicity of chemotherapeutic agents like procarbazine and irinotecan.<sup>21</sup> Because of its good tolerability and intravenous availability LCM is a suitable alternative as add-on AED, e.g. in combination with LEV.<sup>21</sup> Remarkably, we found very limited data on the efficacy of LTG and GBP in glioma patients. LTG is a first line treatment for focal seizures in non-tumour cases and has no enzyme-inducing properties.<sup>93</sup> LTG is considered the most effective AED (together with GBP) in treating elderly adults with focal-onset seizures,<sup>98</sup> and has been considered a suitable option for the treatment of BTRE.<sup>21, 99, 100</sup> Disadvantages of LTG are the need for slow titration, risk of dermatologic reactions, and the interaction with VPA.<sup>93</sup>

It needs to be emphasized that this review article does not provide a complete overview about AEs of AEDs. Initiating a second-line AED did not necessarily indicate failure of AED monotherapy but might have been caused by initiating early polytherapy instead of adequately dose escalation,<sup>25</sup> making it difficult to compare AED treatment failure rates. For example, in the unblinded RCT by Rossetti et al. (2014), patients with primary brain tumors and epilepsy were titrated to monotherapy LEV or PGB, and efficacy and tolerability were assessed. If necessary, LEV was increased to 3000 mg/day leading to relatively less AED discontinuation due to inefficacy, but more because of AEs.<sup>36</sup> In general, a retrospective study design is not the most suitable design to report the AED tolerability accurately. Nonetheless, even in retrospective study designs, treatment failure due to adverse effects rates can reliably be estimated as a change in AED regimen and the reason for this is well reported in medical charts. Therefore, with regard to AEs we focused solely on treatment failure rates. However, most studies reporting treatment failure rates included only a limited number of patients, meaning the reported effect size can vary widely from the true (population) effect size.

To conclude, based on the current limited evidence, monotherapy with LEV, PHT and PGB seem to be most effective in glioma patients, compared to the other AEDs studied (VPA, CBZ, TPM, OXC), of which LEV shows a favorable tolerability as well. TPM and PER appear relatively good choices for add-on treatment, and LEV with PHT as well as LEV with VPA are relatively effective dual therapy combinations. However, due to heterogeneous patient populations and low scientific quality of the studies, results should be interpreted with caution. Although well-powered comparative efficacy RCTs are still lacking, in clinical practice newer AEDs with limited to no interactions, such as LEV and LCM, have become increasingly preferred in glioma patients. As long as clear evidence for

AED treatment in BTRE is absent, recommendations by the International League Against Epilepsy (ILAE) for treating focal seizures in non-tumour cases can be used, considering side effects and drug interactions.<sup>98</sup> Currently, an RCT is being conducted in which LEV and VPA are compared (NCT03048084). Other prospective studies, particularly focusing on AED polytherapy are also warranted. Since improving HRQoL, partly by means of controlling seizures, is one of the main treatment goals in glioma patients with epilepsy, future studies should incorporate appropriate outcome measures that reflect efficacy as much as tolerability of AED treatment. RCT's and well-designed observational studies are desirable for the frequently used and well tolerated AED LTG in addition to the newer AEDs LCM, PER and BRV. Outcomes such as seizure freedom and 50% seizure reduction along with AED treatment failure should be used, adjusting for potential confounders such as tumor status and concomitant tumor treatment. The results of this review may serve as historical control data for future trials. More clinically relevant are probably HRQoL questionnaires.

---

**Funding**

None

**Acknowledgements**

We acknowledge the contribution of Thomas Vissers with his input in the design of the search strategy.

**Conflict of interest**

All authors declare no conflicts of interest.

## References

1. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management *The Lancet Neurology*. 2007 May;6:421-430.
2. Kerkhof M, Vecht CJ. Seizure characteristics and prognostic factors of gliomas *Epilepsia*. 2013 2013;54:12-17.
3. Liigant A, Haldre S, Oun A, Linnamagi U, Saar A, Asser T, et al. Seizure disorders in patients with brain tumors *Eur Neurol*. 2001;45:46-51.
4. Klein M, Engelberts NH, van der Ploeg HM, Kasteleijn-Nolst Trenite DG, Aaronson NK, Taphoorn MJ, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life *Ann Neurol*. 2003 10/2003;54:514-520.
5. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours *Lancet Neurol*. 2004 Mar;3:159-168.
6. Koekkoek JA, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, et al. Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide *J Neurol Neurosurg Psychiatry*. 2015 4/2015;86:366-373.
7. Ruda R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C, et al. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study *Neuro Oncol*. 2013 12/2013;15:1739-1749.
8. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas *J Neurosurg*. 2008 2/2008;108:227-235.
9. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response *Ann Oncol*. 2003 12/2003;14:1722-1726.
10. Koekkoek JAF, Kerkhof M, Dirven L, Heimans JJ, Reijneveld JC, Taphoorn MJB. Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review *Neuro-Oncology*. 2015 2015;17:924-934.
11. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma *Lancet Oncol*. 2014 Aug;15:e395-403.
12. Stupp R, Brada M, van den Bent MJ, Tonn J-C, Pentheroudakis G. High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up *Annals of Oncology*. 2014 9/1/2014;25:101.
13. Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology *Neurology*. 2000 May 23;54:1886-1893.
14. Tremont L, I, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors *Cochrane Database of Systematic Reviews*. 2008 2008.
15. Pulman J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for post-craniotomy seizures *Cochrane Database Syst Rev*. 2013 Feb 28:CD007286.
16. Rossetti AO, Stupp R. Epilepsy in brain tumor patients *Current Opinion in Neurology*. 2010 2010;23:603-609.
17. de Groot M, Reijneveld JC, Aronica E, Heimans JJ. Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment *Brain*. 2012 Apr;135:1002-1016.
18. Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme *Neuro-oncology*. 2013 Jul;15:961-967.
19. Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: New insights and evidence-based management *Oncologist*. 2014 2014;19:751-759.
20. Santos-Pinheiro F, Park M, Liu D, Kwong LN, Cruz S, Levine NB, et al. Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas *Neurooncol Pract*. 2019 May;6:209-217.
21. Armstrong TS, Grant R, Gilbert MR, Lee JW, Norden AD. Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy *Neuro-oncology*. 2016 Jun;18:779-789.
22. Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy *Epilepsia*. 2013 2013;54:97-104.
23. Soffietti R, Baumert BG, Bello L, von DA, Duffau H, Frenay M, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force *Eur J Neurol*. 2010 9/2010;17:1124-1133.
24. Kerrigan S, Grant R. Antiepileptic drugs for treating seizures in adults with brain tumours *Cochrane Database of Systematic Reviews*. 2011 2011.

25. Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme *Neuro Oncol.* 2013 7/2013;15:961-967.
26. Dinapoli L, Maschio M, Jandolo B, Fabi A, Pace A, Sperati F, et al. Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study *Neurol Sci.* 2009 8/2009;30:353-359.
27. Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study *J Neurooncol.* 2009 7/2009;93:349-354.
28. Merrell RT, Anderson SK, Meyer FB, Lachance DH. Seizures in patients with glioma treated with phenytoin and levetiracetam *J Neurosurg.* 2010 12/2010;113:1176-1181.
29. Rosati A, Buttolo L, Stefani R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study *Arch Neurol.* 2010 3/2010;67:343-346.
30. Usery JB, Michael LM, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures *Journal of Neuro-Oncology.* 2010 2010;99:251-260.
31. de GM, Aronica E, Heimans JJ, Reijneveld JC. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma *Neurology.* 2011 8/9/2011;77:532-539.
32. Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life *J Neurooncol.* 2011 8/2011;104:205-214.
33. Bahr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Kortvelyessy P, et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial *Acta Neurochir (Wien).* 2012 2/2012;154:229-235.
34. Calatozzolo C, Pollo B, Botturi A, Dinapoli L, Carosi M, Salmaggi A, et al. Multidrug resistance proteins expression in glioma patients with epilepsy *J Neurooncol.* 2012 10/2012;110:129-135.
35. Michelucci R, Pasini E, Meletti S, Fallica E, Rizzi R, Florindo I, et al. Epilepsy in primary cerebral tumors: The characteristics of epilepsy at the onset (results from the PERNO study-Project of Emilia Romagna Region on Neuro-Oncology) *Epilepsia.* 2013 10/1/2013;54:86-91.
36. Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study *Neuro Oncol.* 2014 4/2014;16:584-588.
37. Wychowski T, Wang H, Buniak L, Henry JC, Mohile N. Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs *Clin Neurol Neurosurg.* 2013 11/2013;115:2365-2369.
38. Rahman Z, Wong CH, Dexter M, Olsson G, Wong M, Gebisky V, et al. Epilepsy in patients with primary brain tumors: The impact on mood, cognition, and HRQOL *Epilepsy Behav.* 2015 7/2015;48:88-95.
39. Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patino A, Arrieta O, et al. Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma *J Neurooncol.* 2018 1/2018;136:363-371.
40. Berntsson SG, Merrell RT, Amirian ES, Armstrong GN, Lachance D, Smits A, et al. Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study *J Neurol.* 2018 4/23/2018.
41. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures *J Neurol.* 2009 9/2009;256:1519-1526.
42. Maschio M, Albani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy *J Neurooncol.* 2006 10/2006;80:97-100.
43. Maschio M, Zarabla A, Maialelli A, Fabi A, Vidiri A, Villani V, et al. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group *Epilepsy Behav.* 2017 8/2017;73:83-89.
44. Ruda R, Pellerino A, Franchino F, Bertolotti C, Bruno F, Mo F, et al. Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study *J Neurooncol.* 2018 1/2018;136:105-114.
45. Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors *Journal of Neurosurgery.* 2013 6/2013;118:1183-1187.
46. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients *J Neurooncol.* 2006 5/2006;78:99-102.

47. Wagner GL, Wilms EB, Van Donselaar CA, Vecht C. Levetiracetam: Preliminary experience in patients with primary brain tumours *Seizure*. 2003 12/2003;12:585-586.
48. Eseonu CI, Eguia F, Garcia O, Kaplan PW, Quinones-Hinojosa A. Comparative analysis of monotherapy versus duotherapy antiseizure drug management for postoperative seizure control in patients undergoing an awake craniotomy *J Neurosurg*. 2017 6/16/2017:1-7.
49. Bech KT, Seyedi JF, Schulz M, Poulsen FR, Pedersen CB. The risk of developing seizures before and after primary brain surgery of low- and high-grade gliomas *Clin Neurol Neurosurg*. 2018 Jun;169:185-191.
50. Casas Parera I, Gonzalez Roffo MA, Baez A, Quintans F, Castellanos Oropeza P, Sanchez Retamar MC. Characterization of seizures (ILAE 1981 and 2017 classifications) and their response to treatment in a cohort of patients with glial tumors: A prospective single center study *eNeurologicalSci*. 2019 Mar;14:51-55.
51. Chonan M, Saito R, Kanamori M, Osawa S, Watanabe M, Suzuki H, et al. Experience of Low Dose Perampamil to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy *Neurologia Medico-Chirurgica*. 2020 Jan;60:37-44.
52. Feyissa AM, Worrell GA, Tatum WO, Chaichana KL, Jentoft ME, Cazares HG, et al. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control *Seizure-European Journal of Epilepsy*. 2019 Jul;69:283-289.
53. Haggiagi A, Avila EK. Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive study *Neurooncol Pract*. 2019 May;6:203-208.
54. Ius T, Pauletto G, Tomasino B, Maieron M, Budai R, Isola M, et al. Predictors of Postoperative Seizure Outcome in Low Grade Glioma: From Volumetric Analysis to Molecular Stratification *Cancers (Basel)*. 2020 Feb 8;12.
55. Kerkhof M, Koekkoek JAF, Vos MJ, van den Bent MJ, Taal W, Postma TJ, et al. Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study *Journal of neuro-oncology*. 2019 May;142:463-470.
56. Maialetti A, Maschio M, Zarabla A, Polimadei C, Papa E, Villani V, et al. Multimodal pathway for brain tumor-related epilepsy patients: Observational study *Acta Neurol Scand*. 2020 Feb 11.
57. Romoli M, Mandarano M, Romozzi M, Eusebi P, Bedetti C, Cesarini EN, et al. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events *Journal of Neurology*. 2019 Sep;266:2273-2276.
58. Suzuki H, Mikuni N, Sugita S, Aoyama T, Yokoyama R, Suzuki Y, et al. Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors *Neurol Med Chir (Tokyo)*. 2020 Mar 15;60:147-155.
59. Solomons MR, Jaunmuktane Z, Weil RS, El-Hassan T, Brandner S, Rees JH. Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better *Neurooncol Pract*. 2020 Mar;7:196-201.
60. Ruda R, Houillier C, Maschio M, Reijneveld JC, Hellot S, De Backer M, et al. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES) *Epilepsia*. 2020 Apr;61:647-656.
61. Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. *Clinical article J Neurosurg*. 2009 8/2009;111:282-292.
62. Hwang SL, Lin CL, Lee KS, Lieu AS, Kuo TH, Chang CZ, et al. Factors influencing seizures in adult patients with supratentorial astrocytic tumors *Acta Neurochirurgica*. 2004 2004;146:589-594.
63. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas *Arch Neurol*. 1995 7/1995;52:717-724.
64. Rosati A, Tomassini A, Pollo B, Ambrosi C, Schwarz A, Padovani A, et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations *J Neurooncol*. 2009 7/2009;93:395-400.
65. Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? *Onkologie*. 2005 8/2005;28:391-396.
66. Zaatreh MM, Firlik KS, Spencer DD, Spencer SS. Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome *Neurology*. 2003 9/9/2003;61:636-641.
67. Zaatreh MM, Spencer DD, Thompson JL, Blumenfeld H, Novotny EJ, Mattson RH, et al. Frontal lobe tumoral epilepsy: clinical, neurophysiologic features and predictors of surgical outcome *Epilepsia*. 2002 7/2002;43:727-733.
68. Simo M, Velasco R, Graus F, Verger E, Gil M, Pineda E, et al. Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy *J Neurooncol*. 2012 7/2012;108:451-458.



69. You G, Sha ZY, Yan W, Zhang W, Wang YZ, Li SW, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study *Neuro Oncol*. 2012 2/2012;14:230-241.
70. Yuan Y, Xiang W, Yanhui L, Ruofei L, Shuang L, Yingjun F, et al. Ki-67 overexpression in WHO grade II gliomas is associated with poor postoperative seizure control *Seizure*. 2013 12/2013;22:877-881.
71. Wang YC, Lee CC, Takami H, Shen S, Chen KT, Wei KC, et al. Awake craniotomies for epileptic gliomas: intraoperative and postoperative seizure control and prognostic factors *J Neurooncol*. 2019 May;142:577-586.
72. Pace A, Bove L, Innocenti P, Pietrangeli A, Carapella CM, Oppido P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients *J Exp Clin Cancer Res*. 1998 12/1998;17:479-482.
73. Warnke PC, Berlis A, Weyerbrock A, Ostertag CB. Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas *Acta Neurochir Suppl*. 1997 1997;68:90-92.
74. Villanueva V, Saiz-Diaz R, Toledo M, Piera A, Mauri JA, Rodriguez-Uranga JJ, et al. NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy *Epilepsy Behav*. 2016 12/2016;65:25-32.
75. Toledo M, Molins A, Quintana M, Santamarina E, Martinez-Ricarte F, Martinez-Saez E, et al. Outcome of cancer-related seizures in patients treated with lacosamide *Acta Neurol Scand*. 2018 1/2018;137:67-75.
76. Maschio M, Dinapoli L, Mingoa M, Sperati F, Pace A, Pompili A, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability *J Neurol*. 2011 11/2011;258:2100-2104.
77. Izumoto S, Miyauchi M, Tasaki T, Okuda T, Nakagawa N, Nakano N, et al. Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel *Anticancer Res*. 2018 Jul;38:4361-4366.
78. Vecht C, Duran-Pena A, Houillier C, Durand T, Capelle L, Huberfeld G. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations *J Neurooncol*. 2017 7/2017;133:603-607.
79. Maschio M, Pauletto G, Zarabla A, Maialetti A, Ius T, Villani V, et al. Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis *Int J Neurosci*. 2019 Jun;129:593-597.
80. Maschio M, Zarabla A, Maialetti A, Giannarelli D, Koudriavtseva T, Villani V, et al. Perampanel in brain tumor-related epilepsy: Observational pilot study *Brain and Behavior*. 2020.
81. Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, et al. Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study *Epileptic Disord*. 2012 12/2012;14:388-397.
82. Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidiri A, et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life *J Neurooncol*. 2012 2/2012;106:651-656.
83. Maschio M, Dinapoli L, Vidiri A, Pace A, Fabi A, Pompili A, et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine *J Exp Clin Cancer Res*. 2009 5/6/2009;28:60.
84. Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy *J Neurooncol*. 2008 1/2008;86:61-70.
85. Lu Y, Yu W, Wang X. Efficacy of topiramate in adult patients with symptomatic epilepsy: an open-label, long-term, retrospective observation *CNS Drugs*. 2009 2009;23:351-359.
86. Striano S, Striano P, Boccella P, Nocerino C, Bilo L. Tiagabine in glial tumors *Epilepsy Res*. 2002 3/2002;49:81-85.
87. Maschio M, Dinapoli L, Zarabla A, Maialetti A, Giannarelli D, Fabi A, et al. Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study *Clin Neuropharmacol*. 2017 5/2017;40:113-119.
88. van der Meer PB, Fiocco M, Koekkoek JAF, Taphoorn MJB, Dirven L. Computation of antiepileptic drug retention rates in the presence of a competing risk *Seizure*. 2019 2019/04/01;67:82.
89. Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, et al. Epileptic seizures in diffuse low-grade gliomas in adults *Brain*. 2013;137:449-462.
90. Ruda R, Soffietti R. What is New in the Management of Epilepsy in Gliomas? *Curr Treat Options Neurol*. 2015 6/2015;17:351.
91. French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? *Therapeutic Advances in Drug Safety*. 2011 2011/08/01;2:141-158.

92. Jaeckle KA, Ballman K, Furth A, Buckner JC. Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma *Neurology*. 2009 10/13/2009;73:1207-1213.
93. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults *Lancet Neurol*. 2011 May;10:446-456.
94. Maschio M, Beghi E, Casazza MML, Colicchio G, Costa C, Banfi P, et al. Patterns of care of brain tumor-related epilepsy. A cohort study done in Italian Epilepsy Center *PLoS One*. 2017;12:e0180470.
95. Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review *Pain*. 2012 Feb;153:359-365.
96. Ford E, Catt S, Chalmers A, Fallowfield L. Systematic review of supportive care needs in patients with primary malignant brain tumors *Neuro-oncology*. 2012 Apr;14:392-404. Review
97. Huppold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, et al. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2016;34:731-739.
98. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes *Epilepsia*. 2013 Mar;54:551-563.
99. Perucca E. Optimizing antiepileptic drug treatment in tumoral epilepsy. 2013;54:97-104.
100. Vecht CJ, Kerkhof M, Duran-Pena A. Seizure prognosis in brain tumors: new insights and evidence-based management *The oncologist*. 2014 Jul;19:751-759.

## Supplementary material

## Supplementary Table 1. Search strategy

Date	Database	Strategy
01-06-2020	PubMed	<p>((("Glioma"[Mesh] OR glioma*[tw] OR neuroglioma*[tw] OR xanthoastrocytoma*[tw] OR xantoastrocytoma*[tw] OR astrocytoma*[tw] OR astro-cytoma*[tw] OR astroglioma*[tw] OR astro-glioma*[tw] OR oligoastrocytoma*[tw] OR oligoastro-cytoma*[tw] OR glioblastom*[tw] OR oligo-blastom*[tw] OR oligodendrogloma*[tw] OR oligo-dendrogloma*[tw] OR oligoden-droglioma*[tw] OR oligodendroblastoma*[tw] OR oligo-dendro-blastoma*[tw] OR brain malign*[tw] OR oligo-dendroblastoma*[tw] OR oligoden-droblastoma*[tw] OR oligodendro-blastoma*[tw] OR brain malign*[tw] OR malignant primary brain*[tw] OR primary malignant brain*[tw] OR malignant brain*[tw] OR glial tumour*[tw] OR glial tumor*[tw] OR glial neoplasm*[tw] OR glial cancer*[tw] OR "glial carcinoma"[tw] OR "glial carcinomas"[tw] OR glial malignan*[tw] OR glial cell tumour*[tw] OR glial cell tumor*[tw] OR glial cell neoplasm*[tw] OR "glial cell cancer"[tw] OR "glial cell cancers"[tw] OR "glial cell carcinoma"[tw] OR "glial cell carcinomas"[tw] OR "glial cell malignancy"[tw] OR "glial cell malignancies"[tw] OR neuroglial tumour*[tw] OR neuroglial tumor*[tw] OR neuroglial neoplasm*[tw] OR "neuroglial cancer"[tw] OR "neuroglial cancers"[tw] OR "neuroglial carcinoma"[tw] OR "neuroglial carcinomas"[tw] OR "neuroglial malignancy"[tw] OR "neuroglial malignancies"[tw] OR "neuroglial cell tumour*[tw] OR "neuroglial cell tumours"[tw] OR "neuroglial cell tumor*[tw] OR "neuroglial cell tumors"[tw] OR "neuroglial cell neoplasm*[tw] OR "neuroglial cell neoplasms"[tw] OR "neuroglial cell cancer"[tw] OR "neuroglial cell cancers"[tw] OR "neuroglial cell carcinoma*[tw] OR "neuroglial cell carcinomas"[tw] OR "neuroglial cell malignancy"[tw] OR "neuroglial cell malignancies"[tw]) OR ("Brain Neoplasms"[Mesh] OR ((tumour*[ti] OR tumor*[ti]) AND ("brain"[ti] OR "brains"[ti] OR "cns"[ti] OR central nervous system*[ti] OR intracranial*[ti] OR cerebral*[ti] OR intracerebral*[ti] OR glial*[ti] OR neuroglia*[ti])) OR tumour of brain*[tw] OR tumor of brain*[tw] OR "tumours of brain*[tw] OR "tumors of brain*[tw] OR tumour of the brain*[tw] OR tumor of the brain*[tw] OR "tumors of the brain*[tw] OR "tumors of the brain*[tw] OR brain tumour*[tw] OR brain tumor*[tw] OR "tumour of cns*[tw] OR tumor of cns*[tw] OR "tumours of cns*[tw] OR "tumors of cns*[tw] OR tumour of the cns*[tw] OR tumor of the cns*[tw] OR "tumours of the cns*[tw] OR "tumors of the cns*[tw] OR cns tumour*[tw] OR cns tumor*[tw] OR "tumour of central nervous system*[tw] OR tumor of central nervous system*[tw] OR "tumours of central nervous system*[tw] OR "tumors of central nervous system*[tw] OR tumour of the central nervous system*[tw] OR tumor of the central nervous system*[tw] OR "tumours of the central nervous system*[tw] OR "tumors of the central nervous system*[tw] OR central nervous system tumor*[tw] OR intracranial tumour*[tw] OR intracranial tumor*[tw] OR cerebral tumour*[tw] OR cerebral tumor*[tw] OR intracerebral tumour*[tw] OR intracerebral tumor*[tw] OR (neoplasm*[ti] AND ("brain*[ti] OR "brains*[ti] OR "cns*[ti] OR central nervous system*[ti] OR intracranial*[ti] OR cerebral*[ti] OR intracerebral*[ti] OR glial*[ti] OR neuroglia*[ti])) OR neoplasm of brain*[tw] OR neoplasms of brain*[tw] OR neoplasm of the brain*[tw] OR "neoplasms of the brain*[tw] OR brain neoplasm*[tw] OR neoplasm of cns*[tw] OR "neoplasms of cns*[tw] OR neoplasm of the cns*[tw] OR "neoplasms of the cns*[tw] OR neoplasm of central nervous system*[tw] OR "neoplasms of central nervous system*[tw] OR neoplasm of the central nervous system*[tw] OR "neoplasms of the central nervous system*[tw] OR central nervous system neoplasm*[tw] OR intracranial neoplasm*[tw] OR cerebral neoplasm*[tw] OR intracerebral neoplasm*[tw] OR (cancer*[ti] AND ("brain*[ti] OR "brains*[ti] OR "cns*[ti] OR central nervous system*[ti] OR intracranial*[ti] OR cerebral*[ti] OR intracerebral*[ti] OR glial*[ti] OR neuroglia*[ti])) OR cancer of brain*[tw] OR "cancers of brain*[tw] OR cancer of the brain*[tw] OR "cancers of the brain*[tw] OR brain cancer*[tw] OR "cancer of cns*[tw] OR "cancers of cns*[tw] OR "cancer of the cns*[tw] OR "cancers of the cns*[tw] OR cns cancer*[tw] OR "cancer of central nervous system*[tw] OR "cancers of central nervous system*[tw] OR cancer of the central nervous system*[tw] OR "cancers of the central nervous system*[tw] OR central nervous system cancer*[tw] OR intracranial cancer*[tw] OR cerebral cancer*[tw] OR "intracerebral cancer*[tw] OR "intracerebral cancers*[tw] OR ((carcinoma*[ti] AND ("brain*[ti] OR "brains*[ti] OR cerebral*[ti] OR intracerebral*[ti] OR glial*[ti] OR neuroglia*[ti])) OR "carcinoma of brain*[tw] OR "carcinomas of brain*[tw] OR "carcinoma of the brain*[tw] OR "carcinomas of the brain*[tw] OR brain carcinoma*[tw] OR cerebral carcinoma*[tw] OR "intracerebral carcinoma*[tw] OR "intracerebral carcinomas*[tw] OR (malignan*[ti] AND (intracranial*[ti] OR cerebral*[ti] OR intracerebral*[ti] OR glial*[ti] OR neuroglia*[ti])) OR cns malignan*[tw] OR central nervous system malignan*[tw] OR intracranial malignan*[tw] OR cerebral malignan*[tw] OR intracerebral malignan*[tw]) AND ("Epilepsy"[Mesh] OR epilep*[tiab] OR seizure*[tiab] OR seizure*[tiab] OR epilep*[ta] OR convulsi*[ta] OR "aura*[tiab] OR aura*[tiab] OR auras*[tiab] OR "Anticonvulsants"[Mesh] OR anticonvul*[tiab] OR anti-convul*[tiab] OR antiepilep*[tiab] OR anti-epilep*[tiab] OR "aed*[ti] OR aed*[ti] OR aeds*[ti] OR "Carbamazepine"[Mesh] OR carbamazepin*[tiab] OR carba-mazepin*[tiab] OR tegretol*[tiab] OR "Clonazepam"[Mesh] OR clonazepam*[tiab] OR "gabapentin"[Supplementary Concept] OR gabapentin*[tiab] OR gaba-pentin*[tiab] OR "lacosamide"[Supplementary Concept] OR lacosamid*[tiab] OR "lamotrigine"[Supplementary Concept] OR lamotrigin*[tiab] OR lamo-trigin*[tiab] OR "oxcarbazepine"[Supplementary Concept] OR oxcarbazepin*[tiab] OR "Phenytoin"[Mesh] OR phenytoin*[tiab] OR fenytain*[tiab] OR "Pregabalin"[Mesh] OR pregabalin*[tiab] OR "topiramate"[Supplementary Concept] OR topiramat*[tiab] OR "Valproic Acid"[Mesh] OR (valproic*[ti] AND acid*[ti]) OR valproic acid*[tiab] OR depakin*[tiab] OR "zonisamide"[Supplementary Concept] OR zonisamid*[tiab] OR "etiracetam"[Supplementary Concept] OR etiracetam*[tiab] OR levetiracetam*[tiab] OR keppra*[tiab] OR "perampanel"[Supplementary Concept] OR perampanel*[tiab] OR "clobazam"[Supplementary Concept] OR clobazam*[tiab] OR "Phenobarbital"[Mesh] OR phenobarbital*[tiab] OR pheno-barbital*[tiab] OR fenobarbital*[tiab] OR feno-barbital*[tiab] OR phenylbarbital*[tiab] OR phenyl-barbital*[tiab] OR fenylbarbital*[tiab] OR fenyl-barbital*[tiab] OR phenylethylbarbitur*[tiab] OR phenyl-ethylbarbitur*[tiab] OR phenyl-ethyl-barbitur*[tiab] OR phenylethylbarbitur*[tiab] OR fenyl-ethylbarbitur*[tiab] OR fenyl-ethyl-barbitur*[tiab] OR phenylethylbarbitur*[tiab] OR phenemal*[tiab] OR phene-mal*[tiab] OR fenemal*[tiab] OR fene-mal*[tiab] OR phenobarbiton*[tiab] OR pheno-barbiton*[tiab] OR fenobarbiton*[tiab] OR feno-barbiton*[tiab] OR hystep*[tiab] OR gardenal*[tiab]) AND ("Treatment Outcome"[Mesh] OR outcome*[tiab] OR effective*[tiab] OR efficac*[tiab] OR treatment fail*[tiab] OR freedom*[tiab] OR seizure free*[tiab] OR seizure reduc*[tiab] OR seizure decreas*[tiab] OR "seizure decline*[tiab] OR seizure control*[tiab] OR seizure duration*[tiab] OR seizure type*[tiab] OR seizure frequen*[tiab] OR seizure respon*[tiab] OR retention rat*[tiab] OR engel scale*[tiab] OR international league against epilep*[tiab] OR (international*[ti] AND league*[ti] AND against*[ti] AND epilep*[ti]) OR "ilae*[tiab] OR ilae*[tiab]) AND english[lang]) NOT ("Adolescent"[Mesh] OR "Child"[Mesh] OR "Infant"[Mesh]) NOT "Adult"[Mesh]) OR ("Animals"[Mesh] NOT "Humans"[Mesh]) OR "Review" [Publication Type] OR "Case Reports" [Publication Type] OR "Comment" [Publication Type] OR "Editorial" [Publication Type])</p>

Date	Database	Strategy
01-06-2020	MEDLINE (OVID-version)	<p>((exp GLIOMA/ OR glioma*.ti,ab,kf. OR neuroglioma*.ti,ab,kf. OR xanthoastrocytoma*.ti,ab,kf. OR xanthoastrocytoma*.ti,ab,kf. OR astrocytoma*.ti,ab,kf. OR astro-cytoma*.ti,ab,kf. OR astroglioma*.ti,ab,kf. OR astro-glioma*.ti,ab,kf. OR oligoastrocytoma*.ti,ab,kf. OR oligoastro-cytoma*.ti,ab,kf. OR glioblastom*.ti,ab,kf. OR glio-blastom*.ti,ab,kf. OR oligodendrogloma*.ti,ab,kf. OR oligo-dendrogloma*.ti,ab,kf. OR oligodendrogloma*.ti,ab,kf. OR oligodendroblastoma*.ti,ab,kf. OR oligo-dendro-blastoma*.ti,ab,kf. OR oligo-dendroblastoma*.ti,ab,kf. OR oligodendroblastoma*.ti,ab,kf. OR oligodendro-blastoma*.ti,ab,kf. OR brain malign*.ti,ab,kf. OR malignant primary brain*.ti,ab,kf. OR primary malignant brain*.ti,ab,kf. OR malignant brain*.ti,ab,kf. OR glial tumour*.ti,ab,kf. OR glial tumor*.ti,ab,kf. OR glial neoplasm*.ti,ab,kf. OR glial cancer*.ti,ab,kf. OR glial carcinoma*.ti,ab,kf. OR glial carcinoma*.ti,ab,kf. OR glial malignan*.ti,ab,kf. OR glial cell tumour*.ti,ab,kf. OR glial cell tumor*.ti,ab,kf. OR glial cell neoplasm*.ti,ab,kf. OR glial cell cancer*.ti,ab,kf. OR glial cell carcinoma*.ti,ab,kf. OR glial cell malignan*.ti,ab,kf. OR neuroglial tumour*.ti,ab,kf. OR neuroglial tumor*.ti,ab,kf. OR neuroglial neoplasm*.ti,ab,kf. OR neuroglial cancer*.ti,ab,kf. OR neuroglial carcinoma*.ti,ab,kf. OR neuroglial malignan*.ti,ab,kf. OR neuroglial cell tumour*.ti,ab,kf. OR neuroglial cell tumor*.ti,ab,kf. OR neuroglial cell neoplasm*.ti,ab,kf. OR neuroglial cell cancer*.ti,ab,kf. OR neuroglial cell carcinoma*.ti,ab,kf. OR neuroglial cell malignan*.ti,ab,kf. OR (exp Brain Neoplasms/ OR (tumour*.ti. OR tumor*.ti.)) AND ("brain".ti. OR "brains".ti. OR "cns".ti. OR central nervous system*.ti. OR intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR tumour o? brain*.ti,ab,kf. OR tumor o? brain*.ti,ab,kf. OR tumours o? brain*.ti,ab,kf. OR tumors o? brain*.ti,ab,kf. OR tumours o? the brain*.ti,ab,kf. OR tumor o? the brain*.ti,ab,kf. OR tumours o? the brain*.ti,ab,kf. OR tumors o? the brain*.ti,ab,kf. OR tumours o? the CNS*.ti,ab,kf. OR tumor o? the CNS*.ti,ab,kf. OR tumours o? the CNS*.ti,ab,kf. OR tumors o? the CNS*.ti,ab,kf. OR CNS tumour*.ti,ab,kf. OR CNS tumor*.ti,ab,kf. OR tumour o? central nervous system*.ti,ab,kf. OR tumor o? central nervous system*.ti,ab,kf. OR tumours o? central nervous system*.ti,ab,kf. OR tumors o? central nervous system*.ti,ab,kf. OR tumour o? the central nervous system*.ti,ab,kf. OR tumor o? the central nervous system*.ti,ab,kf. OR tumours o? the central nervous system*.ti,ab,kf. OR tumors o? the central nervous system*.ti,ab,kf. OR tumour o? the central nervous system tumour*.ti,ab,kf. OR intracranial tumour*.ti,ab,kf. OR intracerebral tumour*.ti,ab,kf. OR (neoplasm*.ti.)) AND ("brain".ti. OR "brains".ti. OR "cns".ti. OR central nervous system*.ti. OR intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR neoplasm o? brain*.ti,ab,kf. OR neoplasms o? brain*.ti,ab,kf. OR neoplasm o? the brain*.ti,ab,kf. OR neoplasms o? the CNS*.ti,ab,kf. OR neoplasms o? the CNS*.ti,ab,kf. OR CNS neoplasm*.ti,ab,kf. OR CNS tumor*.ti,ab,kf. OR neoplasm o? central nervous system*.ti,ab,kf. OR neoplasms o? central nervous system*.ti,ab,kf. OR neoplasm o? the central nervous system*.ti,ab,kf. OR neoplasms o? the central nervous system*.ti,ab,kf. OR central nervous system neoplasm*.ti,ab,kf. OR intracranial neoplasm*.ti,ab,kf. OR cerebral neoplasm*.ti,ab,kf. OR intracerebral neoplasm*.ti,ab,kf. OR ((cancer*.ti.)) AND ("brain".ti. OR "brains".ti. OR "cns".ti. OR central nervous system*.ti. OR intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR cancer o? brain*.ti,ab,kf. OR cancers o? brain*.ti,ab,kf. OR cancer o? the brain*.ti,ab,kf. OR cancer o? the CNS*.ti,ab,kf. OR cancer o? the CNS*.ti,ab,kf. OR brain cancer*.ti,ab,kf. OR cancer o? CNS*.ti,ab,kf. OR cancer o? CNS*.ti,ab,kf. OR cancer o? the CNS*.ti,ab,kf. OR cancer o? the CNS*.ti,ab,kf. OR cancer o? central nervous system*.ti,ab,kf. OR cancer o? central nervous system*.ti,ab,kf. OR cancer o? the central nervous system*.ti,ab,kf. OR cancer o? the central nervous system*.ti,ab,kf. OR central nervous system cancer*.ti,ab,kf. OR intracranial cancer*.ti,ab,kf. OR cerebral cancer*.ti,ab,kf. OR intracerebral cancer*.ti,ab,kf. OR ((carcinoma*.ti.)) AND ("brain".ti. OR "brains".ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR carcinoma o? brain*.ti,ab,kf. OR carcinomas o? brain*.ti,ab,kf. OR carcinoma o? the brain*.ti,ab,kf. OR carcinomas o? the brain*.ti,ab,kf. OR brain carcinoma*.ti,ab,kf. OR cerebral carcinoma*.ti,ab,kf. OR intracerebral carcinoma*.ti,ab,kf. OR ((malignan*.ti.)) AND (intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR CNS malignan*.ti,ab,kf. OR central nervous system malignan*.ti,ab,kf. OR intracranial malignan*.ti,ab,kf. OR cerebral malignan*.ti,ab,kf. OR intracerebral malignan*.ti,ab,kf.)) AND (exp EPILEPSY/ OR epilep*.ab,ti. OR seizure*.ab,ti. OR seizure*.ab,ti. OR epilep*.jn. OR seizure*.jn. OR convuls*.ab,ti. OR "aura".ab,ti. OR aura*.ab,ti. OR auras*.ab,ti. OR exp Anticonvulsants/ OR anticonvul*.ab,ti. OR anti-convul*.ab,ti. OR anti-epilep*.ab,ti. OR anti-epilep*.ab,ti. OR "aed".ti. OR aed*.ti. OR aeds*.ti. OR exp CARBAMAZEPINE/ OR carbamazepin*.ab,ti. OR carba-mazepin*.ab,ti. OR tegretol*.ab,ti. OR exp CLONAZEPAM/ OR clonazepam*.ab,ti. OR gabapentin.nm. OR gabapentin*.ab,ti. OR gaba-pentin*.ab,ti. OR lacosamide.nm. OR lacosamid*.ab,ti. OR lamotrigine.nm. OR lamotrigin*.ab,ti. OR lamo-trigin*.ab,ti. OR oxcarbazepine.nm. OR oxcarbazepin*.ab,ti. OR exp PHENYTOIN/ OR phenytoin*.ab,ti. OR fenytin*.ab,ti. OR exp PREGABALIN/ OR pregabalin*.ab,ti. OR topiramate.nm. OR topiramat*.ab,ti. OR exp Valproic Acid/ OR (valproic*.ti. AND acid*.ti.)) OR (valproic*.ab,ti. adj3 acid*.ab,ti.)) OR depakin*.ab,ti. OR zonisamide.nm. OR zonisamid*.ab,ti. OR etiracetam.nm. OR etiracetam*.ab,ti. OR levetiracetam*.ab,ti. OR keppra*.ab,ti. OR perampanel.nm. OR perampanel*.ab,ti. OR clobazam.nm. OR clobazam*.ab,ti. OR exp PHENOBARBITAL/ OR phenobarbital*.ab,ti. OR pheno-barbital*.ab,ti. OR fenobarbital*.ab,ti. OR fenobarbital*.ab,ti. OR fenobarbital*.ab,ti. OR phenylbarbital*.ab,ti. OR phenylbarbital*.ab,ti. OR fenyl-barbital*.ab,ti. OR fenyl-barbital*.ab,ti. OR phenylethylbarbitur*.ab,ti. OR phenyl-ethylbarbitur*.ab,ti. OR phenyl-ethyl-barbitur*.ab,ti. OR phenylethyl-barbitur*.ab,ti. OR fenylethylbarbitur*.ab,ti. OR fenyl-ethylbarbitur*.ab,ti. OR fenyl-ethyl-barbitur*.ab,ti. OR fenemal*.ab,ti. OR phenemal*.ab,ti. OR phene-mal*.ab,ti. OR fenemal*.ab,ti. OR fene-mal*.ab,ti. OR phenobarbiton*.ab,ti. OR pheno-barbiton*.ab,ti. OR fenobarbiton*.ab,ti. OR fenobarbiton*.ab,ti. OR feno-barbiton*.ab,ti. OR hystep*.ab,ti. OR gardenal*.ab,ti.)) AND (exp Treatment Outcome/ OR outcome*.ab,ti. OR effective*.ab,ti. OR efficac*.ab,ti. OR treatment fail*.ab,ti. OR freedom*.ab,ti. OR seizure free*.ab,ti. OR seizure reduc*.ab,ti. OR seizure decreas*.ab,ti. OR seizure declin*.ab,ti. OR seizure control*.ab,ti. OR seizure duration*.ab,ti. OR seizure type*.ab,ti. OR seizure frequen*.ab,ti. OR seizure respon*.ab,ti. OR retention rat*.ab,ti. OR engel scale*.ab,ti. OR international league against epilep*.ab,ti. OR (international*.ti. AND league*.ti. AND against*.ti. AND epilep*.ti.)) OR (international*.ab,ti. ADJ3 league*.ab,ti. ADJ3 against*.ab,ti. ADJ3 epilep*.ab,ti.)) OR ("ilae".ab,ti. OR ilae*.ab,ti.)) AND english.lg.) NOT (((exp ADOLESCENT/ OR exp CHILD/ OR exp INFANT/)) NOT exp ADULT/) OR (exp Animals/ NOT exp Humans/) OR review.pt. OR case reports.pt. OR comment.pt. OR editorial.pt.)</p>

Date	Database	Strategy
01-06-2020	EMBASE (OVID-version)	<p>((exp glioma/ OR glioma*.ti,ab,kw. OR neuroglioma*.ti,ab,kw. OR xanthoastrocytoma*.ti,ab,kw. OR xantoastrocytoma*.ti,ab,kw. OR astrocytoma*.ti,ab,kw. OR astro-cytoma*.ti,ab,kw. OR astroglioma*.ti,ab,kw. OR astro-glioma*.ti,ab,kw. OR oligoastrocytoma*.ti,ab,kw. OR oligoastro-cytoma*.ti,ab,kw. OR glioblastom*.ti,ab,kw. OR oligo-blastom*.ti,ab,kw. OR oligodendroglioma*.ti,ab,kw. OR oligo-dendroglioma*.ti,ab,kw. OR oligodendro-glioma*.ti,ab,kw. OR oligodendroblastoma*.ti,ab,kw. OR oligo-dendro-blastoma*.ti,ab,kw. OR oligo-dendroblastoma*.ti,ab,kw. OR oligodendroblastoma*.ti,ab,kw. OR oligodendro-blastoma*.ti,ab,kw. OR brain malign*.ti,ab,kw. OR malignant primary brain*.ti,ab,kw. OR primary malignant brain*.ti,ab,kw. OR malignant brain*.ti,ab,kw. OR glioma tumour*.ti,ab,kw. OR glioma tumor*.ti,ab,kw. OR glioma neoplasm*.ti,ab,kw. OR glioma cancer*.ti,ab,kw. OR "glioma carcinoma".ti,ab,kw. OR "glioma carcinomas".ti,ab,kw. OR glioma malignan*.ti,ab,kw. OR glioma cell tumour*.ti,ab,kw. OR glioma cell tumor*.ti,ab,kw. OR glioma cell neoplasm*.ti,ab,kw. OR "glioma cell cancers".ti,ab,kw. OR "glioma cell carcinomas".ti,ab,kw. OR "glioma cell carcinomas".ti,ab,kw. OR "glioma cell malignancy".ti,ab,kw. OR "glioma cell malignancies".ti,ab,kw. OR neuroglial tumour*.ti,ab,kw. OR neuroglial tumor*.ti,ab,kw. OR neuroglial neoplasm*.ti,ab,kw. OR "neuroglial cancer".ti,ab,kw. OR "neuroglial cancers".ti,ab,kw. OR "neuroglial carcinoma".ti,ab,kw. OR "neuroglial carcinomas".ti,ab,kw. OR "neuroglial malignancy".ti,ab,kw. OR "neuroglial malignancies".ti,ab,kw. OR "neuroglial cell tumour".ti,ab,kw. OR "neuroglial cell tumours".ti,ab,kw. OR "neuroglial cell tumor".ti,ab,kw. OR "neuroglial cell neoplasms".ti,ab,kw. OR "neuroglial cell cancer".ti,ab,kw. OR "neuroglial cell cancers".ti,ab,kw. OR "neuroglial cell carcinoma".ti,ab,kw. OR "neuroglial cell carcinomas".ti,ab,kw. OR "neuroglial cell malignancy".ti,ab,kw. OR "neuroglial cell malignancies".ti,ab,kw. OR (exp brain tumor/ OR (tumour*.ti. OR tumor*.ti.) AND ("brain".ti. OR "brains".ti. OR "cns".ti. OR central nervous system*.ti. OR intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR tumour of brain*.ti,ab,kw. OR tumor of brain*.ti,ab,kw. OR "tumours of brain".ti,ab,kw. OR "tumors of brain".ti,ab,kw. OR tumour of the brain*.ti,ab,kw. OR tumor of the brain*.ti,ab,kw. OR brain tumour*.ti,ab,kw. OR brain tumor*.ti,ab,kw. OR "tumour of cns".ti,ab,kw. OR "tumor of cns".ti,ab,kw. OR "tumours of cns".ti,ab,kw. OR "tumors of cns".ti,ab,kw. OR "tumors of the cns".ti,ab,kw. OR tumor of the cns*.ti,ab,kw. OR "tumours of the cns".ti,ab,kw. OR "tumors of the cns".ti,ab,kw. OR cns tumour*.ti,ab,kw. OR cns tumor*.ti,ab,kw. OR "tumour of central nervous system".ti,ab,kw. OR tumor of central nervous system*.ti,ab,kw. OR "tumours of central nervous system".ti,ab,kw. OR "tumors of central nervous system".ti,ab,kw. OR tumour of the central nervous system*.ti,ab,kw. OR tumor of the central nervous system*.ti,ab,kw. OR "tumours of the central nervous system".ti,ab,kw. OR "tumors of the central nervous system".ti,ab,kw. OR central nervous system tumour*.ti,ab,kw. OR central nervous system tumor*.ti,ab,kw. OR intracranial tumour*.ti,ab,kw. OR intracranial tumor*.ti,ab,kw. OR cerebral tumour*.ti,ab,kw. OR cerebral tumor*.ti,ab,kw. OR intracerebral tumour*.ti,ab,kw. OR intracerebral tumor*.ti,ab,kw. OR (neoplasm*.ti.) AND ("brain".ti. OR "brains".ti. OR "cns".ti. OR central nervous system*.ti. OR intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR neoplasm of brain*.ti,ab,kw. OR "neoplasms of brain".ti,ab,kw. OR neoplasm of the brain*.ti,ab,kw. OR "neoplasms of the brain".ti,ab,kw. OR brain neoplasm*.ti,ab,kw. OR neoplasm of cns*.ti,ab,kw. OR "neoplasms of cns".ti,ab,kw. OR neoplasm of the cns*.ti,ab,kw. OR "neoplasms of the cns".ti,ab,kw. OR cns neoplasm*.ti,ab,kw. OR "neoplasm of central nervous system".ti,ab,kw. OR "neoplasms of central nervous system".ti,ab,kw. OR neoplasm of the central nervous system*.ti,ab,kw. OR "neoplasms of the central nervous system".ti,ab,kw. OR central nervous system neoplasm*.ti,ab,kw. OR intracranial neoplasm*.ti,ab,kw. OR intracerebral neoplasm*.ti,ab,kw. OR (cancer*.ti.) AND ("brain".ti. OR "brains".ti. OR "cns".ti. OR central nervous system*.ti. OR intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR cancer of brain*.ti,ab,kw. OR "cancers of brain".ti,ab,kw. OR cancer of the brain*.ti,ab,kw. OR "cancers of the brain".ti,ab,kw. OR brain cancer*.ti,ab,kw. OR "cancer of cns".ti,ab,kw. OR "cancers of cns".ti,ab,kw. OR "cancer of the cns".ti,ab,kw. OR "cancers of the cns".ti,ab,kw. OR cns cancer*.ti,ab,kw. OR "cancer of central nervous system".ti,ab,kw. OR "cancers of central nervous system".ti,ab,kw. OR cancer of the central nervous system*.ti,ab,kw. OR "cancers of the central nervous system".ti,ab,kw. OR central nervous system cancer*.ti,ab,kw. OR intracranial cancer*.ti,ab,kw. OR cerebral cancer*.ti,ab,kw. OR "intracerebral cancer".ti,ab,kw. OR "intracerebral cancers".ti,ab,kw. OR ((carcinoma*.ti.) AND ("brain".ti. OR "brains".ti. OR cerebral*.ti. OR neuroglia*.ti.)) OR "carcinoma of brain".ti,ab,kw. OR "carcinomas of brain".ti,ab,kw. OR "carcinomas of the brain".ti,ab,kw. OR "carcinomas of brain".ti,ab,kw. OR "intracerebral carcinoma".ti,ab,kw. OR "intracerebral carcinomas".ti,ab,kw. OR ((malignan*.ti.) AND (intracranial*.ti. OR cerebral*.ti. OR intracerebral*.ti. OR glial*.ti. OR neuroglia*.ti.)) OR cns malignan*.ti,ab,kw. OR central nervous system malignan*.ti,ab,kw. OR intracranial malignan*.ti,ab,kw. OR cerebral malignan*.ti,ab,kw. OR intracerebral malignan*.ti,ab,kw.)) AND (exp epilepsy/ OR epilep*.ab,ti. OR seizure*.ab,ti. OR seizure*.ab,ti. OR epilep*.jn. OR seizure*.jn. OR convuls*.ab,ti. OR "aura".ab,ti. OR "aura".ab,ti. OR auras*.ab,ti. OR exp anticonvulsive agent/ OR anticonvul*.ab,ti. OR anti-convul*.ab,ti. OR antiepilep*.ab,ti. OR anti-epilep*.ab,ti. OR "aed".ti. OR aed*.ti. OR aeds*.ti. OR exp carbamazepine/ OR carbamazepin*.ab,ti. OR carba-mazepin*.ab,ti. OR tegretol*.ab,ti. OR exp clonazepam/ OR clonazepam*.ab,ti. OR exp gabapentin/ OR gabapentin*.ab,ti. OR gaba-pentin*.ab,ti. OR exp lacosamide/ OR lacosamid*.ab,ti. OR exp lamotrigine/ OR lamotrigin*.ab,ti. OR lamo-trigin*.ab,ti. OR exp oxcarbazepine/ OR oxcarbazepin*.ab,ti. OR exp phenytoin/ OR phenytoin*.ab,ti. OR fenytoin*.ab,ti. OR exp pregabalin/ OR pregabalin*.ab,ti. OR exp topiramate/ OR topiramat*.ab,ti. OR exp valproic acid/ OR (valproic*.ti. AND acid*.ti.) OR (valproic*.ab,ti. ad3 acid*.ab,ti. OR depakin*.ab,ti. OR exp zonisamide/ OR zonisamid*.ab,ti. OR exp etiracetam/ OR etiracetam*.ab,ti. OR levetiracetam*.ab,ti. OR keppra*.ab,ti. OR exp perampanel/ OR perampanel*.ab,ti. OR exp clobazam/ OR clobazam*.ab,ti. OR exp phenobarbital/ OR phenobarbital*.ab,ti. OR pheno-barbital*.ab,ti. OR fenobarbital*.ab,ti. OR phenybarbital*.ab,ti. OR phenyl-barbital*.ab,ti. OR phenylbarbital*.ab,ti. OR phenyl-barbital*.ab,ti. OR phenylethylbarbitur*.ab,ti. OR phenylethylbarbitur*.ab,ti. OR phenyl-ethyl-barbitur*.ab,ti. OR phenylethyl-barbitur*.ab,ti. OR fenylethylbarbitur*.ab,ti. OR phenemal*.ab,ti. OR phenemal*.ab,ti. OR fenemal*.ab,ti. OR fenemal*.ab,ti. OR fene-mal*.ab,ti. OR phenobarbiton*.ab,ti. OR pheno-barbiton*.ab,ti. OR fenobarbiton*.ab,ti. OR feno-barbiton*.ab,ti. OR hystep*.ab,ti. OR gardenal*.ab,ti.) AND (exp treatment outcome/ OR outcome*.ab,ti. OR effective*.ab,ti. OR efficac*.ab,ti. OR treatment fail*.ab,ti. OR freedom*.ab,ti. OR seizure free*.ab,ti. OR seizure reduc*.ab,ti. OR seizure decreas*.ab,ti. OR seizure declin*.ab,ti. OR seizure control*.ab,ti. OR seizure duration*.ab,ti. OR seizure type*.ab,ti. OR seizure frequen*.ab,ti. OR seizure respon*.ab,ti. OR retention rat*.ab,ti. OR engal scale*.ab,ti. OR international league against epilep*.ab,ti. OR (international*.ti. AND league*.ti. AND against*.ti. AND epilep*.ti. OR (international*.ab,ti. AD3) league*.ab,ti. AD3) against*.ab,ti. AD3) epilep*.ab,ti. OR "ilae".ab,ti. OR ilae*.ab,ti.) AND english.lg.) NOT (((exp embryo/ OR exp fetus/ OR exp juvenile/ NOT exp adult/ OR ((exp animal/ OR exp animal experiment/ OR exp nonhuman/) NOT exp human/) OR "review".pt. OR exp case report/ OR editorial.pt. OR conference abstract.pt.)</p>

Date	Database	Strategy
01-06-2020	Web of Science	(TS=(glioma* OR neuroglioma* OR xanthoastrocytoma* OR xantoastrocytoma* OR astrocytoma* OR astro-cytoma* OR astroglioma* OR astro-glioma* OR oligoastrocytoma* OR oligoastro-cytoma* OR glioblastom* OR glio-blastom* OR oligodendrogloma* OR oligo-dendrogloma* OR oligoden-drogloma* OR oligodendroblastoma* OR oligo-dendro-blastoma* OR oligoden-droblastoma* OR oligodendroblastoma* OR brain-malign* OR malignant-primary-brain* OR primary-malignant-brain* OR malignant-brain* OR glial-tumour* OR glial-tumor* OR glial-neoplasm* OR glial-cancer* OR glial-carcinoma* OR glial-malignan* OR glial-cell-tumour* OR glial-cell-tumor* OR glial-cell-neoplasm* OR glial-cell-cancer* OR glial-cell-carcinoma* OR glial-cell-malignan* OR neuroglial-tumour* OR neuroglial-tumor* OR neuroglial-neoplasm* OR neuroglial-cancer* OR neuroglial-carcinoma* OR neuroglial-malignan* OR neuroglial-cell-tumour* OR neuroglial-cell-tumor* OR neuroglial-cell-neoplasm* OR neuroglial-cell-cancer* OR neuroglial-cell-carcinoma* OR neuroglial-cell-malignan*) OR TS=(tumo\$* -of-brain* OR tumo\$* -of-the-brain* OR brain-tumo\$* OR tumo\$* -of-cns* OR tumo\$* -of-the-cns* OR cns-tumo\$* OR tumo\$* -of-central-nervous-system* OR tumo\$* -of-the-central-nervous-system* OR central-nervous-system-tumo\$* OR intracranial-tumo\$* OR cerebral-tumo\$* OR intracerebral-tumo\$* OR neoplasm* -of-brain* OR neoplasm* -of-the-brain* OR brain-neoplasm* OR neoplasm* -of-cns* OR neoplasm* -of-the-cns* OR cns-neoplasm* OR neoplasm* -of-central-nervous-system* OR neoplasm* -of-the-central-nervous-system* OR central-nervous-system-neoplasm* OR intracranial-neoplasm* OR cerebral-neoplasm* OR intracerebral-neoplasm* OR cancer* -of-brain* OR cancer* -of-the-brain* OR brain-cancer* OR cancer* -of-cns OR cancer* -of-the-cns OR cns-cancer* OR cancer* -of-central-nervous-system* OR cancer* -of-the-central-nervous-system* OR central-nervous-system-cancer* OR intracranial-cancer* OR cerebral-cancer* OR intracerebral-cancer* OR carcinoma* -of-brain* OR carcinoma* -of-the-brain* OR brain-carcinoma* OR cerebral-carcinoma* OR intracerebral-carcinoma* OR cns-malignan* OR central-nervous-system-malignan* OR intracranial-malignan* OR cerebral-malignan* OR intracerebral-malignan*) OR TI=((tumo\$*) AND ("brain" OR "brains" OR "cns" OR central-nervous-system* OR intracranial* OR cerebral* OR intracerebral* OR glial* OR neuroglia*)) OR TI=((neoplasm*) AND ("brain" OR "brains" OR "cns" OR central-nervous-system* OR intracranial* OR cerebral* OR intracerebral* OR glial* OR neuroglia*)) OR TI=((cancer*) AND ("brain" OR "brains" OR "cns" OR central-nervous-system* OR intracranial* OR cerebral* OR intracerebral* OR glial* OR neuroglia*)) OR TI=((carcinoma*) AND ("brain" OR "brains" OR cerebral* OR intracerebral* OR glial* OR neuroglia*)) OR TI=((malignan*) AND (intracranial* OR cerebral* OR intracerebral* OR glial* OR neuroglia*)) AND (TS=(epilep* OR seizure* OR seizure* OR convulsi* OR "aura" OR aura* OR auras*) OR SO=(epilep* OR seizure*) OR TS=(anticonvul* OR anti-convul* OR antiepilep* OR anti-epilep* OR carbamazepin* OR carba-mazepin* OR tegretol* OR clonazepam* OR gabapentin* OR gaba-pentin* OR lacosamid* OR lamotrigin* OR lamo-trigin* OR oxcarbazepin* OR phenytoin* OR fenytoin* OR pregabalin* OR topiramam* OR (valproic* NEAR/3 acid*) OR depakin* OR zonisamid* OR etiracetam* OR levetiracetam* OR keppra* OR perampanel* OR clobazam* OR phenobarbital* OR pheno-barbital* OR fenobarbital* OR feno-barbital* OR phenylbarbital* OR phenyl-barbital* OR fenylbarbital* OR fenyl-barbital* OR phenylethylbarbitur* OR phenyl-ethylbarbitur* OR phenyl-ethyl-barbitur* OR phenylethylbarbitur* OR fenyl-ethylbarbitur* OR fenyl-ethylbarbitur* OR fenyl-ethyl-barbitur* OR phenemal* OR phene-mal* OR fenemal* OR fene-mal* OR phenobarbiton* OR pheno-barbiton* OR fenobarbiton* OR feno-barbiton* OR hystep* OR gardenal*) OR TI=(("aed" OR aed* OR aeds* OR (valproic* AND acid*)) AND (TS=(outcome* OR effective* OR efficac* OR treatment-fail* OR freedom* OR seizure-free* OR seizure-reduc* OR seizure-decreas* OR seizure-decline* OR seizure-control* OR seizure-duration* OR seizure-type* OR seizure-frequen* OR seizure-respon* OR retention-rat* OR engel-scale* OR international* NEAR/3 league* NEAR/3 against* NEAR/3 epilep*)) OR TI=((international* AND league* AND against* AND epilep*) OR "ilae" OR ilae*)) AND LA=english



Supplementary Table 2. Efficacy of levetiracetam including all studies

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Levetiracetam (LEV)</b>							
Bahr et al. (2012) <sup>11</sup>	Pros	N=30 (n=25)	GBM n=12; Grade III n=5; LGG n=5; MEN n=3; Unknown n=3 MET n=1; Other n=1;	LEV n=30		1 and 6 (after AED initiation)	1-Month seizure freedom LEV: 21/25=84% 1-Month treatment failure due to AEs (n=0), inefficacy (n=3), or unknown (n=0) LEV: 3/25=12%  6-Month seizure freedom LEV: 13/25=52% 6-Month treatment failure due to AEs (n=0), inefficacy (n=6), or unknown (n=1) LEV: 7/25=28%
Bech et al. (2018) <sup>2</sup>	Retro	N=282 (n=105)	GBM n=205; AA n=25; Other n=19; A=17; AODG n=9; ODG n=7	Vast majority LEV n=97		3 (after surgery)	1-Month seizure freedom AEDs: 80/97=82% 3-Month Seizure freedom AEDs: 66/97=68%
Berritsson et al. (2018) <sup>3</sup>	Retro case-control	N=4533 (n=1087)	GBM n=2772; AA n=529; OA/ODG n=451; A n=373; AO/A/ AODG n=275; Other n=133	LEV n=668; Other n=112; Unknown AED n=173	Other n=161	2 (before the interview)	Seizure freedom AEDs: 731/1087=67%
Breemen et al. (2009) <sup>4</sup>	Discussed under valproic acid						
Calatuzzolo et al. (2012) <sup>5</sup>	Pros	N=35 (n=35)	GBM n=15; AA n=7; A n=6; OA n=4; ODG n=3	LEV n=12; Other: n=19	LEV+Other n=1; Other n=3	Median 12 (unspecified)	Seizure freedom LEV: 7/13=54%
Cardona et al. (2018) <sup>6</sup>	Pros	N=213 (n=136)	GBM n=213	LEV n=82; Other n=54		-	Treatment failure due to inefficacy LEV: 16/82=20%



Supplementary Table 2. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, AEDs	Follow-up (months) AEDs	Outcomes
Casas Parera et al. (2019) <sup>7</sup>	Pros	N=82 (n=75), prophylactic n=20	GBM n=28; A n=22; ODG n=14; AA n=8; AODG n=7; Other n=3	LEV n=43; Other n=32	-	-	Seizure freedom (excl. prophylactic) LEV: 41/43=95% Treatment failure due to inefficacy (excl. prophylactic) LEV: 2/43=5%
Chonan et al. (2019) <sup>8</sup>	Discussed under perampanel						
De Groot et al. (2011) <sup>9</sup>	Pros clinical trial	N=35 (n=35)	GBM n=15; AODG n=6; AA n=4; A n=3; ODG n=3; AOA n=2; OA n=1	LEV n=35	-	6 (after AED initiation)	6-Month seizure freedom LEV: 21/35=59% 6-Month $\geq$ 50% Seizure reduction LEV: 26/35=74% 6-Month treatment failure due to AEs LEV: 1/35=3%
Dinapoli et al. (2009) <sup>10</sup>	Case series	N= 18 (n=18)	GBM n=3; AA n=3; A n=3; OA n=3; ODG n=3; MEN n=2; Other n=1	LEV n=18	-	6 (after AED initiation)	6-Month seizure freedom LEV: 16/18=89% 6-Month $\geq$ 50% seizure reduction LEV: 18/18=100% 6-Month treatment failure due to AEs (n=0) or inefficacy (n=0) LEV=0/18=0%
Eseonu et al. (2018) <sup>11</sup>	Retro	N=81 (n=81), prophylactic n=36	Grade IV n=27; Grade II n=27; Grade III n=17; Other n=8; MET n= 2	LEV n=46	LEV+PHT n=30; LEV+Other n=5	6 (after surgery)	6-Month seizure freedom monotherapy (excl. prophylactic) LEV:15/25=60% 6-Month seizure freedom (excl. prophylactic) LEV+PHT(+/-Other): 18/20=90%
Feyissa et al. (2019) <sup>12</sup>	Retro	N=68 (n=59), prophylactic n=13	GBM n=31; AA n=16; ODG n=14; A n=6; AODG n=1	LEV n=48; Other n=11	-	Median 15 (after surgery)	Seizure freedom (excl. prophylactic) AEDs: 31/46=67%

Supplementary Table 2. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Haggiagi & Avila (2018) <sup>13</sup>	Retro	N=39 (n=39)	ODG n=39		Mono- (n=18) and polytherapy (n=21) LEV+/- Other n=26; Other n=13	Median n=12 temozolomide cycles (after temozolomide initiation)	≥50% Seizure reduction AEDs: 35/39=90%
Ius et al. (2020) <sup>14</sup>	Retro	N=155 (n=155)	A; n=111; ODG n=44	LEV n=96; CBZ n=22; PHT n=10	Other n=27	12 (after surgery)	12-Month seizure freedom: 110/155=71%
Kerkhof et al. (2013) <sup>15</sup>	Discussed under valproic acid						
Kerkhof et al. (2019) <sup>16</sup>	Pros	N=71 (n=71), AED withdrawal n=46	A/ODG/OA n=41; AA/AODG/AOA n=30	LEV n=41; VPA n=16; Other n=14		Median 20 (after AED initiation)	1-Month seizure freedom (excl. AED withdrawal) AEDs: 25/25=100% 3-Month seizure freedom (excl. AED withdrawal) AEDs: 25/25=100% 6-Month seizure freedom (excl. AED withdrawal) AEDs: 24/25=96% 9-Month seizure freedom (excl. AED withdrawal) AEDs: 24/25=96% 12-Month seizure freedom (excl. AED withdrawal) AEDs: 24/25=96%
Lim et al. (2009) <sup>17</sup>	RCT, unblinded	N=29 (n=29)	GBM n=9; AA n=4; A n=4; ODG n=2; AOA n=2; AODG n=1; Grade I n=1	LEV n=20; PHT n=9		6 (after AED initiation/surgery)	6-Month seizure freedom LEV: 18/20=90% 6-Month treatment failure due to AEs (n=0), inefficacy (n=0), or unknown (n=5) LEV: 6/20=30%

Supplementary Table 2. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Maialelli et al. (2020) <sup>18</sup>	Pros	N=33 (n=33)	HGG n=14; LGG n=12; Other n=7	LEV n=10; Other n=11	LEV+Other n=9; Other n=3	6 (after rehabilitation)	6-Month seizure freedom AEDs: 26/33=79% 6-Month ≥50% Seizure reduction AEDs: 28/33=85%
Maschio et al. (2006) <sup>19</sup>	Pros clinical trial	N=19 (n=19)	GBM n=7; A n=6; AA n=5; MEN n=1	LEV+Other n=19		Median 20 (after AED initiation)	Seizure freedom last follow-up LEV: 9/19=47% 6-Month ≥50% seizure reduction LEV: 14/19=74% (ref. Maschio et al. 2017) Treatment failure due to AEs LEV: 0/19=0%
Maschio et al. (2011) <sup>20</sup>	Pros clinical trial	N=29 (n=29)	GBM n=9; AODG n=6; LGA n=5; AA n=4; MEN n=2; Other n=2; ODG n=1;	LEV n=29		12 (after AED initiation)	12-Month seizure freedom LEV: 21/29=72% 12-Month ≥50% Seizure reduction LEV: 28/29=97% 12-Month treatment failure due to AEs (n=1), inefficacy (n=2), or other (n=2) LEV: 5/29=17%
Maschio et al. (2017) <sup>21</sup>	Discussed under lacosamide						
Merrel et al. (2010) <sup>22</sup>	Pros	N=76 (n=76)	GBM n=49; LGG n=27	LEV n=51; PHT n=25		1 and minimum of 6 (after surgery)	Seizure freedom LEV: 24/51=47%; PHT: 10/25=40% 1-Month treatment failure due to AEs (n=1) and clinicians preference (n=0) LEV: 1/36=3%, due to AEs (n=5), or clinicians preference (n=11) PHT: 16/40=40%

Supplementary Table 2. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Michelucci et al. (2013) <sup>23</sup>	Pros	N=100 (n=97)	GBM n=52; AA n=15; ODG n=10; A n=9; AODG n=5; Other n=4; AOA n=3; Grade I n=2;	Mono- (n=64) and polytherapy (n=33): LEV n=63; OXC n=33; PHT n=16; CBZ n=10; Other n=8		6 (after surgery)	6-Month seizure freedom AEDs: 39/100=39%
Newton et al. (2006) <sup>24</sup>	Retro	N=41 (n=41)	AA n=13; GBM n=12; MET n=7; ODG n=5; LGG n=2; Other n=2	LEV n=8	LEV+Other n=33	1 (after AED initiation)	1-Month seizure freedom in gliomas LEV: 17/32=53% 1-Month ≥50% seizure reduction in gliomas LEV: 28/32=88% 1-Month treatment failure due to AEs LEV: 1/41=2%
Rahman et al. (2015) <sup>25</sup>	Pros	N=81 (n=55)	GBM n=27; ODG n=20; MEN n=13; A n=8; Grade I n=7; OA n=4; Other n=2	LEV n=21; Other n=11	LEV+Other n=9; Other n=14	6 (after AED initiation)	6-Month seizure freedom AEDs: 32/55=58%
Romoli et al. (2019) <sup>26</sup>	Pros	N=18 (n=18)	GBM n=8; ODG n=6; A n=3; OA n=1	LEV n=18		-	≥50% Seizure reduction LEV: 18/18=100%
Rosati et al. (2010) <sup>27</sup>	Pros clinical trial	N=176 (n=82)	GBM n=118; AA n=23; ODG n=13; A n=8; AODG n=7; AOA n=6; Grade I n=1	LEV n=82		Mean 13 (after AED initiation)	Seizure freedom LEV: 75/82=91% Treatment failure due to AEs (n=2) or inefficacy (n=7) LEV: 9/82=11%
Rossetti et al. (2014) <sup>28</sup>	Discussed under pregabalin						
Rudà et al. (2018) <sup>29</sup>	Discussed under lacosamide						

Supplementary Table 2. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, AEDs	Follow-up (months) AEDs	Outcomes
Rudà et al. (2020) <sup>30</sup>	Discussed under lacosamide						
Saria et al. (2013) <sup>31</sup>	Discussed under lacosamide						
Solomons et al. (2019) <sup>32</sup>	Retro	N=74 (n=66)	ODG n=32; A n=26; OA n=7; Other n=9	Mono- and polytherapy: LEV +/- Other n=44; Other n=22		12 (after AED initiation)	12-Month seizure freedom 38/66=57%
Suzuki et al. (2020) <sup>33</sup>	Retro	N=36 (n=33), prophylactic n=6	A n=22; ODG n=14	LEV n=22; Other n=11		Median 32 (after surgery)	Treatment failure due to AEs (n=0) or inefficacy (n=13) (excl. prophylactic) AEDs: 13/27=48%
Usery et al. (2010) <sup>34</sup>	Pros	N=17 (n=17)	GBM n=7; Other n=5; ODG n=2; MEN n=2; AA n=1;	LEV n=17		1 (after AED initiation/surgery)	1-Month seizure freedom LEV: 15/17=88% 1-Month ≥50% Seizure reduction LEV: 16/17=94% 1-Month treatment failure due to AEs (n=0) or inefficacy (n=0) LEV: 0/17=0%
Wagner et al. (2003) <sup>35</sup>	Pros clinical trial	N=26 (n=26)	HGG n=18; LGG n=8	LEV n=1	LEV+Other n=25	Median 9 (after AED initiation)	Seizure freedom LEV: 10/26=38% >50% Seizure reduction LEV: 19/26=73% Treatment failure due to AEs (n=1) or unknown (n=1) LEV: 2/26=8%
Wychowksi et al. (2013) <sup>36</sup>	Retro	N=172 (n=124), prophylactic n=70	GBM n=172	LEV 28; PHT 13; Other n=4	Other n=9	-	Seizure freedom (excl. prophylactic) AEDs: 26/54=48% Treatment failure due to AEs (excl. prophylactic) LEV: 5/28=18%; PHT 5/13=38%

**Antiepileptic drugs (AEDs):** CBZ=Carbamazepine; LEV=Levetiracetam; OXC=Oxcarbazepine; PHT=Phenytoin, **Histology:** A=(Pleomorphic) astrocytoma grade II; AA=Anaplastic (pleomorphic) astrocytoma; AOA=Anaplastic oligoastrocytoma; AODG=Anaplastic oligodendroglioma; GBM=Glioblastoma; HGG=High grade glioma; LGG=Low grade glioma; MEN=Meningioma; MET=Metastasis; OA=Oligoastrocytoma; ODG=Oligodendroglioma grade II, **General abbreviations:** AEs=Adverse effects; Excl.=excluding; N=number of patients; Pros=prospective; RCT=randomized controlled trial; Retro=retrospective

**Supplementary Table 3.** Efficacy of phenytoin, valproic acid, and carbamazepine including all studies.

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Phenytoin (PHT)</b>						
ChaiChana et al. (2009) <sup>37</sup>	Retro	N=648 (n=153)	GBM n=505; AA n=143	Preoperative AEDs: mono- (n=111) and polytherapy (n=42): PHT n=102; LEV n=13; DVX n=12; Other n=19; Unknown unclear	6 and 12 (after surgery)	6-Month seizure freedom AEDs: 79/91=87% 12-Month seizure freedom AEDs: 51/66=77%
Chang et al. (2008) <sup>38</sup>	Retro	N=332 (n=284)	A n=129; OA n=109; ODG n=95	PHT n=159; CBZ n=59; DVX n=29; PB n=26; Other n=15;	3 (before surgery), 6 and 12 (after surgery)	3-Month seizure freedom PHT: 84/159=53%; CBZ: 22/59=37%; PB: 11/26=42%; Divalproex sodium: 14/29=48% 6-Month seizure freedom AEDs: 169/253=67%
Eseonu et al. (2018) <sup>11</sup>	Discussed under levetiracetam					
Hwang et al. (2004) <sup>39</sup>	Retro	N=101 (n=101), prophylactic n=87	GBM n=57; AA n=27; A n=17	PHT n=101	1, 3 and 12 (after surgery)	1-Month seizure freedom (excl. prophylactic) PHT: 12/14=86% 3-Month seizure freedom (excl. prophylactic) PHT: 11/14=79% 12-Month seizure freedom (excl. prophylactic) PHT: 9/14=64%

Supplementary Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Klein et al. (2003) <sup>40</sup>	Discussed under carbamazepine					
Merrel et al. (2010) <sup>22</sup>	Discussed under levetiracetam					
Moots et al. (1995) <sup>41</sup>	Retro	N=65 (n=63), prophylactic n=34	GBM n=47; AA n=18	Mono- and polytherapy: PHT n=62; PB n=18; CBZ n=12; Other n=4	Median 14 (after surgery)	Seizure freedom (excl. prophylactic) PHT: 8/29=28% Treatment failure due to inefficacy (excl. prophylactic) PHT: 8/29=28%
Rosati et al. (2009) <sup>42</sup>	Pros	N=64 (n=27)	GBM n=43; AODG n=7; AA 5; AOA n=3; ODG n=3; A n=3	PHT n=10; Other n=15	Median 19 (after surgery)	Seizure freedom PHT: 5/10=50%
Wick et al. (2005) <sup>43</sup>	Retro	N=107 (n=107), prophylactic n=32, unclear n=7	GBM n=45; AA n=17; ODG n=16; AODG n=14; A n=13; Grade I n=1; Other n=1	PHT n=35; VPA n=34; CBZ n=27; Unclear n=11	12 (after surgery)	12-Month seizure freedom (incl. prophylactic) PHT: 17/35=49%; VPA: 19/34=56%; CBZ: 8/27=30% 12-Month treatment failure due to AEs (incl. prophylactic) PHT: 12/35=34%; VPA: 7/34=21%; CBZ: 7/27=26%;
Wychowski et al. (2013) <sup>36</sup>	Discussed under levetiracetam					
Zaatreh et al. (2002) <sup>44</sup>	Discussed under carbamazepine					

Supplementary Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Zaatreh et al. (2003) <sup>45</sup>	Retro	N=68 (68)	A n=31; Grade I n=19; ODG n=12; AA n=4; MEN n=2	Mono- and polytherapy: PHT n=62; CBZ n=59; PB n=32; VPA n=28; PRI n=17; LTG n=12; GBP n=10; Other n=21	-	≥50% Seizure reduction: PHT: 26/62=42%; CBZ 24/59=41%; PB 10/32=31%; VPA 9/28=32%; PRI 4/17=23%; LTG 3/12=25%; GBP 2/10=20% Treatment failure due to AEs: PHT: 10/62=16%; CBZ 10/59=17%; PB 3/32=9%; VPA 5/28=18%; PRI 2/17=12%; LTG 2/12=17%; GBP 2/10=20%
Valproic acid (VPA)						
Breemen et al. (2009) <sup>4</sup>	Retro	N=140 (n=99)	GBM n=56; A n=22; MET n=19; AODG n=10; AA n=8; ODG n=8; MEN n=6; Grade I n=4; OA n=3; Other n=3; AOA n=1	VPA n=80; CBZ n=12; Other n=7	Minimum of 6 (after AED initiation)	Seizure freedom: VPA (without LEV +/- other AEDs): 15/29=52%; VPA+LEV (+/- other AEDs): 16/27=59%; LEV (without VPA +/- other AEDs): 5/16=31% Treatment failure (any reason) in gliomas mono- (first-line) AED: 56/85=66%
Kerkhof et al. (2013) <sup>15</sup>	Retro	N=145 (n=145)	GBM n=145	VPA n=100; LEV n=37; Other n=8	Minimum of 6 (after AED initiation)	Seizure freedom VPA: 41/100=41%; LEV: 16/37=43% Seizure freedom VPA+LEV: 32/59=54% Treatment failure (any reason) VPA: 66/100=66%; LEV: 15/37=41%
Klein et al. (2003) <sup>40</sup>	Discussed under carbamazepine					
Simó et al. (2012) <sup>46</sup>	Pros	N=101 (n=60), prophylactic n=7	GBM n=101	VPA n=38; LEV n=12; EIAEDs n=10	-	Treatment failure (incl. prophylactic, any reason) AEDs: 13/60=22%



Supplementary Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs AEDs	Follow-up (months) AEDs	Outcomes
Wang et al. (2019) <sup>47</sup>	Retro	N=41 (n=41)	Grade II n=19; Grade III n=12; Grade IV n=10	VPA n=21; LEV n=11; Other n=4	6 (after surgery)	6-Month treatment failure due to inefficacy AEDs: 5/37=14%
Wick et al. (2005) <sup>43</sup>	Discussed under phenytoin					
You et al. (2012) <sup>48</sup>	Retro	N=508 (n=502), prophylactic n=154	OA n=231; A n=229; ODG n=48	VPA n=444; Other n=8; Unknown n=2	6 and 12 (after surgery)	6-Month seizure freedom (excl. prophylactic) AEDs: 215/329=65%. 12-Month seizure freedom (excl. Prophylactic AEDs: 90/304=30%.
Yuan et al. (2013) <sup>49</sup>	Retro	N=93 (n=65)	ODG n=36; OA n=29; A n=28	VPA n>95%; Other n<5%	12 (after surgery)	12-Month seizure freedom AEDs: 37/65=57%
Zaatreh et al. (2002) <sup>44</sup>	Discussed under carbamazepine					
Zaatreh et al. (2003) <sup>45</sup>	Discussed under phenytoin					
Carbamazepine (CBZ)						
Chang et al. (2008) <sup>38</sup>	Discussed under phenytoin					
Klein et al. (2003) <sup>40</sup>	Cross-sectional (seizure history retro)	N= 156 (n=114)	A n=109; ODG n=38; OA n=9	CBZ n=29; VPA: n=13; PHT n=20; Other n=2	12 (after primary treatment)	12-Month seizure freedom CBZ: 16/29=55%; PHT 7/20=35%; VPA 8/13=62%
Pace et al. (1998) <sup>50</sup>	Discussed under phenobarbital					

Supplementary Table 3. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Warnke et al. (1997) <sup>51</sup>	Retro	N=80 (n=80), prophylactic n=8	A n=80	CBZ n=58; PHT n=12; PB n=10	6 (after radiosurgery)	6-Month seizure freedom (incl. prophylactic) CBZ: 16/58=28%
Wick et al. (2005) <sup>43</sup>	Discussed under phenytoin					
Zaatreh et al. (2002) <sup>44</sup>	Retro	N=37 (n=37)	ODG n=12; LGG n=10; MEN n=8; Grade I n=4; AA n=1; OA n=1; Other n=1	Mono- and polytherapy: CBZ n=33; PHT n=32; Other n=24; PB n=23; VPA n=18; GBP n=14; LTG n=10	-	≥50% Seizure reduction CBZ: 12/33=36%; PHT: 11/32=34%; PB 11/23=48%; VPA 3/18=17%; GBP 3/14=21%; LTG 2/10=20% Treatment failure due to AEs CBZ: 8/33=24%; PHT: 7/32=22%; PB: 4/23=17%; VPA: 5/18=28%; GBP 2/14=14%; LTG: 2/10=20%
Zaatreh et al. (2003) <sup>45</sup>	Discussed under phenytoin					

**Antiepileptic drugs (AEDs):** CBZ=Carbamazepine; DVX=Divalproex sodium; ELAEDs=Enzyme-inducing antiepileptic drugs; GBP=Gabapentin; LTG=Lamotrigine; LEV=Levetiracetam; PB=Phenobarbital; PRJ=Primidone; PHT=Phenytoin; VPA=Valproic acid. **Histology:** A=(Pleiomorphic) astrocytoma grade II; AA=Anaplastic (pleiomorphic) astrocytoma; AOA=Anaplastic oligoastrocytoma; AODG=Anaplastic oligodendroglioma; GBM=Glioblastoma; HGG=High grade glioma; LGG=Low grade glioma; MEN=Meningioma; MET=Metastasis; OA=Oligoastrocytoma; ODG=Oligodendroglioma grade II. **General abbreviations:** AEs=Adverse effects; Excl.=excluding. Incl.=including; Pros=prospective; Retro=retrospective

**Supplementary Table 4.** Efficacy of lacosamide, phenobarbital, perampanel, pregabalin, oxcarbazepine, topiramate, tiagabine, zonisamide, gabapentin, lamotrigine, divalproex sodium, primidone, vigabatrin including all studies.

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) / AEDs	Outcomes
Lacosamide (LCM)							
Maschio et al. (2011) <sup>52</sup>	Pros clinical trial	N=14 (n=14)	GBM n=5; AA n=2; AOA n=2; A n=2; AODG n=1; ODG n=1; GC n=1	N AEDs	LCM+Other n=14	3, 6 and 9 (after AED initiation)	3-Month treatment failure due to AEs (n=1) or inefficacy (n=0) LCM: 1/14=7% 6-Month treatment failure due to AEs (n=1) or inefficacy (n=0) LCM: 1/14=7% 9-Month seizure freedom LCM: 6/14=38% 9-Month $\geq$ 50% seizure reduction LCM: 11/14=79%
Maschio et al. (2017) <sup>21</sup>	Pros (compared to a historical control group) clinical trial	N=25 (n=25)	A n=8; AA n=6; GBM n=5; ODG n=3; AODG n=2; AOA n=1	N AEDs	LCM+LEV(+/- other) n=15; LCM+Other n=10	3 and 6 (after AED initiation)	3-Month seizure freedom LCM: 8/25=32% 3-Month $\geq$ 50% seizure reduction LCM: 19/25=76% 3-Month treatment failure due to AEs (n=0), poor compliance (n=4) or inefficacy (n=1) LCM: 5/25=20% 6-Month seizure freedom LCM: 7/25=28% 6-Month $\geq$ 50% seizure reduction LCM: 19/25=76% 6-Month treatment failure due to AEs (n=0), poor compliance (n=4) or inefficacy (n=1) LCM: 5/25=20%

Supplementary Table 4. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) / AEDs	Outcomes
Rudà et al. (2018) <sup>29</sup>	Pros clinical trial	N=71 (n=71)	A n=44; ODG/OA n=27		LCM+LEV(+/- Other) n=60; LCM+Other 11	3, 6 and 9 (after AED initiation)	3-Month seizure freedom LCM: 30/71=42% 3-Month ≥50% seizure reduction LCM: 53/71=75%  6-Month seizure freedom LCM: 28/65=43% 6-Month ≥50% seizure reduction LCM: 50/65=77%  9-Month seizure freedom LCM: 29/58=50% 9-Month ≥50% seizure reduction LCM: 50/58=86% 9-Month treatment failure due to AEs (n=2), inefficacy (n=1), or other reasons (n=1) LCM: 4/71=6%
Rudà et al. (2020) <sup>30</sup>	Pros	N=93 (n=93)	ODG n=32; A n=29; OA n=13; Other n=16; MEN n=3		LCM+LEV(+/- Other) n=60; LCM+Other n=33	6 (after AED initiation)	6-Month seizure freedom LCM: 30/86=35% 6-Month ≥50% seizure reduction LCM: 66/86=77% 6-Month treatment failure due to AEs (n=5), inefficacy (n=2), or other reasons (n=7) LCM: 14/93=15%
Saria et al. (2013) <sup>31</sup>	Retro	N=70 (n=70)	GBM n=28; A/OA/ODG n=26; AA/AODG n=12; MEN n=3; Other n=1	LCM n=12	LCM+LEV n=35; LCM+Other n=23	Median 6 (after AED initiation)	≥50% Seizure reduction LCM: 38/70=66% Treatment failure due to inefficacy LCM: 16/70=23%

Supplementary Table 4. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Toledo et al. (2018) <sup>53</sup>	Retro	N=48 (n=48)	GBM n=14; A/OA n=8; MET n=7; AA n=4; Grade I n=4; MEN n=3; Other n=8	LCM+Other n=48	Minimum of 6 (after AED initiation)	Seizure freedom LCM: 8/48=17% ≥50% Seizure reduction LCM: 32/48=67% Treatment failure due to AEs (n=0) or inefficacy (n=1) LCM: 1/48=2%
Villanueva et al. (2016) <sup>54</sup>	Retro	N= 105 (n=105)	A n=42; GBM n=13; MET n=12; MEN n=11; Grade I n=10; ODG n=7; OA n=5; Other n=2; Unknown n=2; GC n=1;	LCM n=3 LCM+Other n=102	3 and 6 (after AED initiation)	3-Month seizure freedom LCM: 32/105=30% 3-Month ≥50% seizure reduction LCM: 71/105=68% 3-Month treatment failure due to AEs (n=1), inefficacy (n=0), or other reasons (n=0) LCM: 1/105=1%  6-Month seizure freedom LCM: 25/97=26% 6-Month ≥50% seizure reduction LCM: 64/97=66% 6-Month treatment failure due to AEs (n=5), inefficacy (n=1), or other reasons (n=2) LCM: 8/105=8%
<b>Phenobarbital (PB)</b>						
Chang et al. (2008) <sup>38</sup>	Discussed under phenytoin					
Maschio et al. (2009) <sup>55</sup>	Discussed under oxcarbazepine					
Pace et al. (1998) <sup>50</sup>	Pros	N= 119 (n=119), prophylactic n=57	GBM n=50; AA n=38; A n=31	PB n=59; CBZ n=35; VGB n=25	Mean 27 (after surgery)	Seizure freedom (excl. prophylactic) PB: 12/28=43%; CBZ: 9/22=41%; VGB: 6/12=50% Treatment failure due to AEs or inefficacy (incl. prophylactic) PB: 38/59=64%; CBZ: 14/35=40%; VGB: 8/25=32%

Supplementary Table 4. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) / AEDs	Outcomes
Zaatreh et al. (2002) <sup>44</sup>	Discussed under carbamazepine						
Zaatreh et al. (2003) <sup>45</sup>	Discussed under phenytoin						
<b>Perampanel (PER)</b>							
Chohan et al. (2019) <sup>8</sup>	Retro	N= 18 (n=18)	GBM n=7; AA n=5; ODG n=3; A n=2; AODG; n=1	PER+LEV n=18		1, 3, 6, 9, 12 (after AED initiation)	1-Month seizure freedom: 10/18=56% 1-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  3-Month seizure freedom: 8/18=44% 3-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  6-Month seizure freedom: 8/18=44% 6-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  9-Month seizure freedom: 8/18=44% 9-Month treatment failure due to AEs or inefficacy PER: 0/18=0%  12-Month seizure freedom: 8/18=44% 12-Month treatment failure due to AEs or inefficacy PER: 0/18=0%
Izumoto et al. (2018) <sup>56</sup>	Retro	N=12 (n=12)	AODG n=5; AA n=3; GBM n=2; A n=1; OA n=1	PER+Other n=12		6 (after AED initiation)	6-Month seizure freedom PER: 6/10=60% 6-Month ≥50% seizure reduction PER: 10/10=100% 6-Month treatment failure due to AEs PER: 1/12=8%

Supplementary Table 4. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
Maschio et al. (2018) <sup>57</sup>	Retro	N=11 (n=11)	A n=4; GBM n=3; AA n=2; AOA n=2	PER+Other n=11	12 (after AED initiation)	12-Month seizure freedom PER: 5/11=45% 12-Month $\geq$ 50% seizure reduction PER: 9/11=82% 12-Month treatment failure due to AEs PER: 0/11=0%
Maschio et al. (2020) <sup>58</sup>	Pros clinical trial	N=26 (n=26)	GBM n=7; AA n=7; A n=5; ODG n=3; MET n=2; MEN n=1; AOA n=1	PER+Other n=26	6 (after AED initiation)	6-Month seizure freedom PER: 8/26=31% 6-Month $\geq$ 50% seizure reduction PER: 23/26=88% 6-Month treatment failure due to AEs (n=2) or inefficacy (n=0) PER: 2/26=8%
Vecht et al. (2017) <sup>59</sup>	Pros	N=12 (n=12)	A/OA/ODG n=6; AA/AO/AODG n=3; GBM n=2; Grade I n=1	PER+Other n=12	Median 6 (after AED initiation)	Seizure freedom PER: 6/12=50% $\geq$ 50% Seizure reduction PER: 9/12=75% Treatment failure due to AEs (n=1) or inefficacy (n=1) PER: 2/12=17%
Pregabalin (PGB)						
Maschio et al. (2012) <sup>60</sup>	Pros clinical trial	N=25 (n=25)	GBM n=6; AA n=4; AODG n=3; AOA n=3; A n=2; MET n=2; MEN n=2; GC n=2; OA n=1; MEN n=2	PGB+Other n=25	6 (after AED initiation)	6-Month seizure freedom PGB: 9/25=36% 6-Month $\geq$ 50% Seizure reduction PGB: 19/25=76% 6-Month treatment failure due to AEs (n=2) or inefficacy (n=5) PGB: 7/25=28%
Rossetti et al. (2014) <sup>28</sup>	RCT, unblinded phase II trial	N=52 (n=52)	HGG n=37; Recurrent tumor n=16	PGB n=27; LEV n=25	12 (after AED initiation)	12-Month seizure freedom PGB: 18/24=75%; LEV: 17/25=68% 12-Month treatment failure AEs (n=7) or inefficacy (n=4) PGB: 11/27=41%; AEs (n=7) or inefficacy (n=1) LEV: 8/25=32%

Supplementary Table 4. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, N AEDs	Polytherapy, N AEDs	Follow-up (months) / AEDs	Outcomes
<b>Oxcarbazepine (OXC)</b>							
Maschio et al. (2009) <sup>55</sup>	Retro	N=70 (n=70)	OXC group: MET n=12; AA n=10; A n=6; GBM n=4; MEN=2; OA n=1 Traditional AED group: GBM n=16; A n=8; AA n=5; AODG n=4; ODG n=2	OXC n=35; Traditional AED group (PB n=24; Other n=11) n=35		Mean OXC 16; traditional AED group 14	Seizure freedom OXC: 22/35=63%; Traditional AED group: 16/35=46% Treatment failure due to AEs OXC: 3/35=9%; PB 11/24=46%; Traditional AED group: 15/35=43%
Maschio et al. (2012) <sup>61</sup>	Pros clinical trial	N=25 (n=25)	GBM n=12; AA n=4; GC n=3; A n=2; AODG n=1 AOA n=1; Grade I n=1; MEN n=1	OXC n=25		12 (after surgery)	12-Month seizure freedom OXC: 10/25=40% 12-Month $\geq$ 50% seizure reduction OXC: 22/25=88% 12-Month treatment failure due to AEs (n=6) or inefficacy (n=3) OXC: 9/25=36%
<b>Topiramate (TPM)</b>							
Lu et al. (2009) <sup>62</sup>	Retro	N=227 (n=227)	LGG n=54; Other n=173	TPM n=14	TPM+Other n=40	12 (after AED initiation)	12-Month seizure freedom mono- polytherapy TPM: 10/14=71%; 24/40=60% 12-Month $\geq$ 50% seizure reduction mono- and polytherapy TPM: 12/14=86%; 28/40=70%
Maschio et al. (2008) <sup>63</sup>	Pros clinical trial	N=47 (n=47)	Grade III n=20; LGG n=13; GBM n=8; MEN n=4; MET n=2	TPM n=47		3, 6 and 12 (after AED initiation)	3-Month seizure freedom TPM: 27/45=60% 3-Month $\geq$ 50% seizure reduction TPM: 34/45=76% 3-Month treatment failure due to AEs (n=2) or inefficacy (n=0) TPM: 2/47=4%



Supplementary Table 4. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) AEDs	Outcomes
<b>Clonazepam (CZP)</b>						
Koekkoek et al. (2016) <sup>64</sup>	Pros	N=25 (n=13)	GBM n=13; AA n=3; A n=3; AODG=2; Unknown n=2; AOA=1; OA=1;	CZP n=13	Median 3 (after AED initiation)	Seizure freedom CZP: 8/13=62%
<b>Tiagabine (TGB)</b>						
Striano et al. (2002) <sup>65</sup>	Pros	N=11 (n=11)	ODG n=6; A n=4; GBM n=1; A n=3; Grade I n=1	TGB+Other n=11	12 (after AED initiation)	12-Month seizure freedom TGB: 3/11=27% 12-Month ≥50% seizure reduction TGB: 7/11=64% 12-Month treatment failure due to AEs (n=2) or inefficacy (n=1) TGB: 3/11=27%
<b>Zonisamide (ZNS)</b>						
Maschio et al. (2017) <sup>66</sup>	Pros	N=13 (n=13)	GBM n=6; MEN n=3; OA n=2; ODG n=1; MET n=1	ZNS+Other n=13	6 (after AED initiation)	6-Month ≥50% seizure reduction ZNS: 7/13=54% 6-Month treatment failure due to AEs (n=0) or inefficacy (n=0) ZNS= 0/13=0%

Supplementary Table 4. Continued

Article	Study design	N study (N AEDs)	Histology, N study	Monotherapy, Polytherapy, N AEDs	Follow-up (months) / AEDs	Outcomes
<b>Gabapentin (GBP)</b>						
Zaatreh et al. (2002) <sup>44</sup>	Discussed under carbamazepine					
Zaatreh et al. (2003) <sup>45</sup>	Discussed under phenytoin					
<b>Lamotrigine (LTG)</b>						
Zaatreh et al. (2002) <sup>44</sup>	Discussed under carbamazepine					
Zaatreh et al. (2003) <sup>45</sup>	Discussed under phenytoin					
<b>Divalproex sodium (DVX)</b>						
Chang et al. (2008) <sup>38</sup>	Discussed under phenytoin					
<b>Primidone (PRI)</b>						
Zaatreh et al. (2003) <sup>45</sup>	Discussed under phenytoin					
<b>Vigabatrin (VGB)</b>						
Pace et al. (1998) <sup>50</sup>	Discussed under phenobarbital					
<b>Antiepileptic drugs (AEDs):</b> CBZ=Carbamazepine; CZP=Clonazepam; DVX=Divalproex sodium; GBP=Gabapentin; LCM=Lacosamide; LEV=Levetiracetam; OXC=Oxcarbazepine; PB=Phenobarbital; PGB=Pregabalin; PRI=Primidone; PHT=Phenytoin; TGB=Tiagabine; TPM=Topiramate; VGB=Vigabatrin; ZNS=Zonisamide; <b>Histology:</b> A=(Pleomorphic) astrocytoma grade II; AA=Anaplastic (pleomorphic) astrocytoma; AOA=Anaplastic oligoastrocytoma; AODG=Anaplastic oligodendrogloma; GBM=Glioblastoma; GC=Gliomatosis cerebri; HGG=High grade glioma; LGG=Low grade glioma; MEN=Meningioma; MET=Metastasis; OA=Oligoastrocytoma; ODG=Oligodendrogloma grade II. <b>General abbreviations:</b> AEs=Adverse effects; Pros=prospective; Retro=retrospective						

Supplementary Table 5. Weighted averages of all included studies.

Follow-up	Seizure freedom, %		>50% reduction, %		Treatment failure (any reason), %		Treatment failure (inefficacy), %		Treatment failure (adverse effects), %	
	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-
<b>Levetiracetam (LEV)</b>										
1-month	86	54	94	88	5	2	7	0	1	2
3-month	75	40	-	75	-	0	-	0	-	-
6-month	60	43	82	76	14	13	10	2	1	5
9-month	96	49	-	86	-	0	-	0	-	-
12-month	74	55	97	-	24	0	6	0	15	-
unknown	66	51	100	68	20	4	16	-	5	2
<b>Phenytoin (PHT)</b>										
1-month	86	-	-	-	40	-	-	-	13	-
3-month	55	-	-	-	-	-	-	-	-	-
6-month	72	90	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	65	-	-	-	34	-	-	-	34	-
unknown	36	-	-	39	31	18	28	-	38	18
<b>Valproic acid (VPA)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	65	-	-	-	14	-	14	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	37	-	-	-	21	-	-	-	21	-
unknown	43	56	-	26	55	22	-	-	-	22
<b>Carbamazepine (CBZ)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	37	-	-	-	-	-	-	-	-	-
6-month	28	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	43	-	-	-	26	-	-	-	26	-
unknown	43	-	-	39	64	20	-	-	-	20
<b>Lacosamide (LCM)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	37	-	71	-	5	-	1	-	1
6-month	-	33	-	73	-	12	-	2	-	5
9-month	-	49	-	85	-	6	-	2	-	4
12-month	-	-	-	-	-	-	-	-	-	-
unknown	-	17	-	59	-	14	-	13	-	2
<b>Phenobarbital (PB)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	42	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-
unknown	44	-	-	38	59	13	-	-	46	13
<b>Perampanel (PER)</b>										
1-month	-	56	-	-	-	0	-	0	-	0
3-month	-	44	-	-	-	0	-	0	-	0
6-month	-	41	-	92	-	5	-	0	-	5
9-month	-	44	-	-	-	0	-	0	-	0
12-month	-	45	-	82	-	0	-	0	-	0
unknown	-	50	-	75	-	17	-	8	-	8

Supplementary Table 5. Continued

Follow-up	Seizure freedom, %		>50% reduction, %		Treatment failure (any reason), %		Treatment failure (inefficacy), %		Treatment failure (adverse effects), %	
	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-
<b>Pregabalin (PGB)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	36	-	76	-	28	-	20	-	8
9-month	-	-	-	-	-	-	-	-	-	-
12-month	75	-	-	-	41	-	15	-	26	-
unknown	-	-	-	-	-	-	-	-	-	-
<b>Oxcarbazepine (OXC)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	40	-	88	-	36	-	12	-	24	-
unknown	63	-	-	-	9	-	-	-	9	-
<b>Topiramate (TPM)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	60	-	76	-	4	-	0	-	4	-
6-month	59	-	77	-	6	-	0	-	6	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	60	60	78	70	6	-	0	-	6	-
unknown	-	-	-	-	-	-	-	-	-	-
<b>Clonazepam (CZP)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-
unknown	62	-	-	-	-	-	-	-	-	-
<b>Tiagabine (TGB)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	27	-	64	-	27	-	9	-	18
unknown	-	-	-	-	-	-	-	-	-	-
<b>Zonisamide (ZNS)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	54	-	0	-	0	-	0
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-
unknown	-	-	-	-	-	-	-	-	-	-
<b>Gabapentin (GBP)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-

Supplementary Table 5. Continued

Follow-up	Seizure freedom, %		>50% reduction, %		Treatment failure (any reason), %		Treatment failure (inefficacy), %		Treatment failure (adverse effects), %	
	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-	Mono-	Poly-
unknown	-	-	-	21	-	17	-	-	-	17
<b>Lamotrigine (LTG)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-
unknown	-	-	-	23	-	18	-	-	-	18
<b>Divalproex sodium (DVX)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	48	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-
unknown	-	-	-	-	-	-	-	-	-	-
<b>Primidone (PRI)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-
unknown	-	-	-	24	-	12	-	-	-	12
<b>Vigabatrin (VGB)</b>										
1-month	-	-	-	-	-	-	-	-	-	-
3-month	-	-	-	-	-	-	-	-	-	-
6-month	-	-	-	-	-	-	-	-	-	-
9-month	-	-	-	-	-	-	-	-	-	-
12-month	-	-	-	-	-	-	-	-	-	-
unknown	43	-	-	-	64	-	-	-	-	-

Mono-=monotherapy; Poly-=polytherapy

## References

1. Bahr O, Hermisson M, Rona S, et al. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. *Acta Neurochir (Wien.)*. 2/2012 2012;154(2):229-235.
2. Bech KT, Seyedi JE, Schulz M, Poulsen FR, Pedersen CB. The risk of developing seizures before and after primary brain surgery of low- and high-grade gliomas. *Clin Neurol Neurosurg*. Jun 2018;169:185-191.
3. Berntsson SG, Merrell RT, Amirian ES, et al. Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. *J Neurol*. 4/23/2018 2018.
4. van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. *J Neurol*. 9/2009 2009;256(9):1519-1526.
5. Calatozzolo C, Pollo B, Botturi A, et al. Multidrug resistance proteins expression in glioma patients with epilepsy. *J Neurooncol*. 10/2012 2012;110(1):129-135.
6. Cardona AF, Rojas L, Wills B, et al. Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. *J Neurooncol*. 1/2018 2018;136(2):363-371.
7. Casas Parera I, Gonzalez Roffo MA, Baez A, Quintans F, Castellanos Oropeza P, Sanchez Retamar MC. Characterization of seizures (ILAE 1981 and 2017 classifications) and their response to treatment in a cohort of patients with glial tumors: A prospective single center study. *eNeurologicalSci*. Mar 2019;14:51-55.
8. Chonan M, Saito R, Kanamori M, et al. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. *Neurologia Medico-Chirurgica*. Jan 2020;60(1):37-44.
9. de GM, Aronica E, Heimans JJ, Reijneveld JC. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. *Neurology*. 8/9/2011 2011;77(6):532-539.
10. Dinapoli L, Maschio M, Jandolo B, et al. Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. *Neurol Sci*. 8/2009 2009;30(4):353-359.
11. Eseonu CI, Eguia F, Garcia O, Kaplan PW, Quinones-Hinojosa A. Comparative analysis of monotherapy versus duotherapy antiseizure drug management for postoperative seizure control in patients undergoing an awake craniotomy. *J Neurosurg*. Jun 2018;128(6):1661-1667.
12. Feyissa AM, Worrell GA, Tatum WO, et al. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. *Seizure-European Journal of Epilepsy*. Jul 2019;69:283-289.
13. Haggiagi A, Avila EK. Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive study. *Neurooncol Pract*. May 2019;6(3):203-208.
14. Ius T, Pualetto G, Tomasino B, et al. Predictors of Postoperative Seizure Outcome in Low Grade Glioma: From Volumetric Analysis to Molecular Stratification. *Cancers (Basel)*. Feb 8 2020;12(2).
15. Kerkhof M, Dielemans JC, van Breemen MS, et al. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. *Neuro Oncol*. 7/2013 2013;15(7):961-967.
16. Kerkhof M, Koekkoek JAF, Vos MJ, et al. Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study. *Journal of neuro-oncology*. May 2019;142(3):463-470.
17. Lim DA, Tarapore P, Chang E, et al. Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. *J Neurooncol*. 7/2009 2009;93(3):349-354.
18. Maialetti A, Maschio M, Zarabla A, et al. Multimodal pathway for brain tumor-related epilepsy patients: Observational study. *Acta Neurol Scand*. Feb 11 2020.
19. Maschio M, Albani F, Baruzzi A, et al. Levetiracetam therapy in patients with brain tumour and epilepsy. *J Neurooncol*. 10/2006 2006;80(1):97-100.
20. Maschio M, Dinapoli L, Sperati F, et al. Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. *J Neurooncol*. 8/2011 2011;104(1):205-214.
21. Maschio M, Zarabla A, Maialetti A, et al. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. *Epilepsy Behav*. 8/2017 2017;73:83-89.
22. Merrell RT, Anderson SK, Meyer FB, Lachance DH. Seizures in patients with glioma treated with phenytoin and levetiracetam. *J Neurosurg*. 12/2010 2010;113(6):1176-1181.

23. Michelucci R, Pasini E, Meletti S, et al. Epilepsy in primary cerebral tumors: The characteristics of epilepsy at the onset (results from the PERNO study-Project of Emilia Romagna Region on Neuro-Oncology). *Epilepsia*. 10/1/2013 2013;54(SUPPL.7):86-91.
24. Newton HB, Goldlust SA, Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. *J Neurooncol*. 5/2006 2006;78(1):99-102.
25. Rahman Z, Wong CH, Dexter M, et al. Epilepsy in patients with primary brain tumors: The impact on mood, cognition, and HRQOL. *Epilepsy Behav*. 7/2015 2015;48:88-95.
26. Romoli M, Mandarano M, Romozzi M, et al. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events. *Journal of Neurology*. Sep 2019;266(9):2273-2276.
27. Rosati A, Buttolo L, Stefani R, Todeschini A, Cenzato M, Padovani A. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. *Arch Neurol*. 3/2010 2010;67(3):343-346.
28. Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R. Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. *Neuro Oncol*. 4/2014 2014;16(4):584-588.
29. Ruda R, Pellerino A, Franchino F, et al. Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. *J Neurooncol*. 1/2018 2018;136(1):105-114.
30. Rudà R, Houillier C, Maschio M, et al. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). *Epilepsia*. 2020;61(4):647-656.
31. Saria MG, Corle C, Hu J, et al. Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors. *Journal of Neurosurgery*. 6/2013 2013;118(6):1183-1187.
32. Solomons MR, Jaunmuktane Z, Weil RS, El-Hassan T, Brandner S, Rees JH. Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better. *Neurooncol Pract*. Mar 2020;7(2):196-201.
33. Suzuki H, Mikuni N, Sugita S, et al. Molecular Aberrations Associated with Seizure Control in Diffuse Astrocytic and Oligodendroglial Tumors. *Neurol Med Chir (Tokyo)*. Mar 15 2020;60(3):147-155.
34. Usery JB, Michael LM, Sills AK, Finch CK. A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. *Journal of Neuro-Oncology*. 2010 2010;99(2):251-260.
35. Wagner GL, Wilms EB, Van Donselaar CA, Vecht C. Levetiracetam: Preliminary experience in patients with primary brain tumours. *Seizure*. 12/2003 2003;12(8):585-586.
36. Wychowski T, Wang H, Buniak L, Henry JC, Mohile N. Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. *Clin Neurol Neurosurg*. 11/2013 2013;115(11):2365-2369.
37. Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A. Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. *J Neurosurg*. 8/2009 2009;111(2):282-292.
38. Chang EF, Potts MB, Keles GE, et al. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. *J Neurosurg*. 2/2008 2008;108(2):227-235.
39. Hwang SL, Lin CL, Lee KS, et al. Factors influencing seizures in adult patients with supratentorial astrocytic tumors. *Acta Neurochirurgica*. 2004 2004;146(6):589-594.
40. Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. *Ann Neurol*. 10/2003 2003;54(4):514-520.
41. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. *Arch Neurol*. 7/1995 1995;52(7):717-724.
42. Rosati A, Tomassini A, Pollo B, et al. Epilepsy in cerebral glioma: timing of appearance and histological correlations. *J Neurooncol*. 7/2009 2009;93(3):395-400.
43. Wick W, Menn O, Meisner C, et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? *Onkologie*. 8/2005 2005;28(8-9):391-396.
44. Zaatreh MM, Spencer DD, Thompson JL, et al. Frontal lobe tumoral epilepsy: clinical, neurophysiologic features and predictors of surgical outcome. *Epilepsia*. 7/2002 2002;43(7):727-733.
45. Zaatreh MM, Firlik KS, Spencer DD, Spencer SS. Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome. *Neurology*. 9/9/2003 2003;61(5):636-641.
46. Simo M, Velasco R, Graus F, et al. Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. *J Neurooncol*. 7/2012 2012;108(3):451-458.
47. Wang YC, Lee CC, Takami H, et al. Awake craniotomies for epileptic gliomas: intraoperative and postoperative seizure control and prognostic factors. *J Neurooncol*. May 2019;142(3):577-586.

48. You G, Sha ZY, Yan W, et al. Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. *Neuro Oncol.* 2/2012 2012;14(2):230-241.
49. Yuan Y, Xiang W, Yanhui L, et al. Ki-67 overexpression in WHO grade II gliomas is associated with poor postoperative seizure control. *Seizure.* 12/2013 2013;22(10):877-881.
50. Pace A, Bove L, Innocenti P, et al. Epilepsy and gliomas: incidence and treatment in 119 patients. *J Exp Clin Cancer Res.* 12/1998 1998;17(4):479-482.
51. Warnke PC, Berlis A, Weyerbrock A, Ostertag CB. Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas. *Acta Neurochir Suppl.* 1997 1997;68:90-92.
52. Maschio M, Dinapoli L, Mingoia M, et al. Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. *J Neurol.* 11/2011 2011;258(11):2100-2104.
53. Toledo M, Molins A, Quintana M, et al. Outcome of cancer-related seizures in patients treated with lacosamide. *Acta Neurol Scand.* 1/2018 2018;137(1):67-75.
54. Villanueva V, Saiz-Diaz R, Toledo M, et al. NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy. *Epilepsy Behav.* 12/2016 2016;65:25-32.
55. Maschio M, Dinapoli L, Vidiri A, et al. The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. *J Exp Clin Cancer Res.* 5/6/2009 2009;28:60.
56. Izumoto S, Miyauchi M, Tasaki T, et al. Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel. *Anticancer Res.* Jul 2018;38(7):4361-4366.
57. Maschio M, Pauletto G, Zarabla A, et al. Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis. *Int J Neurosci.* Jun 2019;129(6):593-597.
58. Maschio M, Zarabla A, Maialetti A, et al. Perampanel in brain tumor-related epilepsy: Observational pilot study. *Brain and Behavior.* 2020;10(6):e01612.
59. Vecht C, Duran-Pena A, Houillier C, Durand T, Capelle L, Huberfeld G. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. *J Neurooncol.* 7/2017 2017;133(3):603-607.
60. Maschio M, Dinapoli L, Sperati F, et al. Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. *Epileptic Disord.* 12/2012 2012;14(4):388-397.
61. Maschio M, Dinapoli L, Sperati F, et al. Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. *J Neurooncol.* 2/2012 2012;106(3):651-656.
62. Lu Y, Yu W, Wang X. Efficacy of topiramate in adult patients with symptomatic epilepsy: an open-label, long-term, retrospective observation. *CNS Drugs.* 2009 2009;23(4):351-359.
63. Maschio M, Dinapoli L, Zarabla A, et al. Outcome and tolerability of topiramate in brain tumor associated epilepsy. *J Neurooncol.* 1/2008 2008;86(1):61-70.
64. Koekkoek JA, Postma TJ, Heimans JJ, Reijneveld JC, Taphoorn MJ. Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study. *Support Care Cancer.* 4/2016 2016;24(4):1633-1638.
65. Striano S, Striano P, Boccella P, Nocerino C, Bilo L. Tiagabine in glial tumors. *Epilepsy Res.* 3/2002 2002;49(1):81-85.
66. Maschio M, Dinapoli L, Zarabla A, et al. Zonisamide in Brain Tumor-Related Epilepsy: An Observational Pilot Study. *Clin Neuropharmacol.* 5/2017 2017;40(3):113-119.





